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ABSTRACT 
 
Grace O. Silva: Comprehensive Characterization of DNA Copy Number Alterations in Mouse 
and Human Breast Tumors 
(Under the direction of Charles M. Perou) 
 
 Breast cancer is a heterogeneous disease as evident through the diversity observed 
between the molecularly identified “intrinsic subtypes”. These intrinsic subtypes are based upon 
patterns of gene expression, are predictive of relapse-free survival, overall survival, and 
responsiveness to treatment. Furthermore, these subtypes are in part driven by specific genomic 
DNA copy number alterations (CNAs), such that the identification of these intrinsic subtype-
defining genetic events is of research and clinical value.  
 To robustly identify breast cancer “driver” genes within frequently occurring DNA 
CNAs, we implemented multiple integrative strategies using genomic data from various human 
breast tumors and genetically engineered mouse (GEM) mammary models. One strategy, a cross-
species conservation based method, identified “conserved genes” that are the subtype-specific 
DNA copy number altered genes found in both human breast tumors and GEM mammary 
tumors. Another strategy, incorporated gene expression signatures of oncogenic pathway activity 
to identify patterns of oncogenic signaling within each breast cancer subtype that correlated 
directly with DNA CNAs. In both strategies, additional functional data from genome-wide RNA-
mediated interference screens and/or a molecular interaction network analysis were included 
highlighting multiple Basal-like-specific 1q21-23 amplified genes and also amplified genes 
unique in highly proliferative luminal breast tumors. 
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 In addition to using CNAs as a base for identifying therapeutic targets, we demonstrated 
that CNAs play other important roles in the advancement of “personalized medicine”. For 
example, when tumor DNA is used as the source DNA for genotyping, we demonstrate that 
CNAs should be taken into consideration as they can lead to erroneous classification of germline 
genotypes. We examined two separate breast cancer cohorts and observed frequent loss of 
heterozygosity at the CYP2D6 locus, which is a predictive marker of tamoxifen response. As 
result, when tumor tissue was used to determine germline CYP2D6 genotype, we observed 
departure from Hardy Weinberg equilibrium and misclassification of intermediate metabolizers 
(of tamoxifen) as either extensive or poor metabolizers. 
 In summary, my work utilized multiple genomic data types to develop novel methods of 
analysis and data visualization to identify driver gene(s) within regions of DNA copy number 
change, which can and should be used to guide personalized treatment decisions. 
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CHAPTER 1 
INTRODUCTION 
 
 
 Breast cancer is a heterogeneous disease that is characterized by distinct histological 
forms, genetic alterations, and patient outcomes. In addition, breast cancer is the most common 
cancer in women living in the Unities States and is also common in women living in less 
developed countries across the world. In 2012, the World Health Organization reported that an 
estimated 1.67 million new cases of breast cancer occurred among women worldwide [1].  In 
2014, the estimated new cases of breast cancer in the United States was 14% of all cancer cases, 
whereas the estimated deaths was 6.8% of all cancer deaths [2]. Interestingly, the NCI SEER 
program demonstrated that between 2002-2011 the death rates have falling yearly at an average 
of 1.9% [2]. This decrease in death rates attests to the improvements in screening, and patient 
treatment options including the advancement of hormone and HER2 targeted therapies.  
 Genomic studies of breast cancer have highlighted the molecular differences observed 
between, and even within, tumors. Genome-wide gene expression pattern analyses identified the 
molecular subtypes existing within breast cancer. These “intrinsic subtypes” demonstrate many 
genetic differences and also varying frequency of clinical features such as differences in 
incidence, survival (both relapse-free and overall), and responsiveness to therapies. Breast 
tumors are categorized into therapeutic groups using clinical-pathological markers based on the 
estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor
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receptor (HER2; also known as ERBB2). The presence of ER, PR and HER2 proteins dictates 
the administration of specific targeted drug therapies. For example, patients with amplified 
and/or over-expressed HER2 are treated with trastuzumab, a monoclonal antibody targeting 
HER2 [3], while all ER and/or PR positive (+) patients are treated with endocrine therapy 
(tamoxifen or aromatase inhibitors) [4]. However, there are subgroups of HER2+ patients with 
worsen response to trastuzumab [5, 6] and also ER+ patients that failed to response to endocrine 
therapies [7, 8]. In addition, there are the poor prognoses “triple-negative (-)” breast cancer 
(TNBC) patients that lack the expression of ER, PR and HER2, and therefore are not candidates 
to receive standard endocrine or trastuzumab therapy options. This heterogeneity in 
responsiveness, even within more homogenous clinical groups like ER+/HER2- patients, 
suggested that additional genetic diversity exists that must be responsible for this behavior. 
Therefore, the focus of this thesis was to identify some of this genetic heterogeneity by using the 
DNA copy number landscape as an arena of potential causation. 
 
DNA Copy Number Alterations as Drivers of Carcinogenesis 
 Numerous somatic mutations occur in all cancer cells and some are known to have 
important clinical implications [9]. These types of genetic mutations included base substitutions, 
small insertions and deletions, translocation, inversions and copy number alterations. Copy 
number alterations (CNAs) are biologically relevant due to gene changes that may affect gene 
expression levels, function, and/or sequence [10, 11]. Specifically, CNAs are imbalances that 
lead to an altered diploid status and result in regions of gains (amplifications) or losses 
(deletions) of genetic information. CNAs range in size, varying in the number of base pairs 
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altered and can also encompass just a handful of bases or even millions of bases encompassing 
hundreds of genes [10, 12]. 
 Somatic CNAs, which are separate from germline copy number variations, are common 
in cancer and specific CNAs are associated with numerous cancer types [12, 13]. Frequently 
occurring CNAs are important in understanding the cellular defects that promote cancer and the 
identification of potential therapeutic strategies [11, 14]. A shining example of this was the copy 
number gain and therapeutic targeting of HER2 in breast cancer, which has now literally saved 
thousands of lives. The current and future challenge is in identifying alterations that promote 
cancer growth from passenger mutations in the many existing CNAs where we do not have an 
obvious candidate like HER2 or MYC [15]. Specifically, copy number losses could lead to 
deletion of tumor suppressor genes, whereas copy number gains could lead to amplification of 
oncogenes [10, 11]; thus the identification of these regions and their potential driver genes are of 
great value. 
 The development of microarray technology provided an exciting new resource for 
estimating CNAs across the genome. In our work, the two array-based technologies used to infer 
CNAs include oligonucleotide array-based comparative genomic hybridization (aCGH) and 
single nucleotide polymorphism (SNP) array platforms. Both technologies were able to infer 
relative copy number values at specific known locations across the genome by using the ratio 
from a simultaneous analysis of tumor and reference DNAs [16, 17]. However, there are caveats 
about using relative copy number values, as the actual DNA content of cancer cells (ploidy) may 
be unknown or difficult to determine, and also cancer cells can be heterogeneous comprising of 
subclones with and without specific CNAs [18–20]. In addition, tumor tissue can be 
contaminated with an unknown amount of normal cells, thus complicating estimates of copy 
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number change. Today, even more computationally consuming and expensive resources are 
currently in development that infers CNAs through single-cell array-based technologies and 
next-generation sequencing data. However, despite all these caveats, microarray-based (and now 
sequencing-based) assessments of genome-wide DNA copy number levels are feasible, robust, 
and yield a large amount of clinically useful data.  
 One benefit of current microarray based technologies includes the ability to specify 
unique regions of the genome with higher coverage or target an even distribution genome-wide 
[11, 17, 21].  Specifically, aCGH analysis can use bacterial artificial chromosomes, cDNAs, or 
long oligonucleotides to target specific regions of the genome [11, 21]. Genomic DNA from 
tumor and normal/reference are uniquely fluorescently labeled and hybridized onto the arrays 
[11, 17, 21]. Relative copy number values are inferred by measuring the fluorescence intensity 
ratio, between tumor and reference [11, 17, 21]. In addition, aCGH can detect whole 
chromosome aneuplodies and submicroscopic deletions and duplications [11, 21]. However, 
because aCGH arrays co-hybridize the tumor with the reference DNA, aCGH arrays may miss 
copy-neutral alterations and regions of LOH, if the LOH is a copy neutral event. 
 SNP arrays use short-base-pair sequences (i.e. regions of single nucleotide 
polymorphisms) to target genomic regions [16, 22]. Unlike aCGH arrays, SNP arrays do not 
require the reference/normal sample to be hybridized along with the target of interest [16, 22]. 
However, we ran SNP arrays on matching normal samples to create relative copy number ratios 
from the two SNP arrays.  Relative copy number is inferred at each SNP by comparing the ratio 
of combined intensity signal at both alleles from a target sample against the reference [16, 22]. 
Additionally, SNP arrays provided genotyping information by also determining the minor-allele 
frequency, the relative proportion of one allele with respect to total intensity signal [16, 22]. 
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Therefore, a benefit of SNP arrays is the ability to identify copy-neutral loss of heterozygosity 
events across the genome [16, 22]. However, a limitation of SNP arrays is the coverage, being 
restricted by the location of SNPs throughout the genome.  
 To ultimately identify regions of the genome where CNAs have occurred, two main 
additional analyses are performed on data produced from aCGH or SNP array platforms. The 
first stage is the normalization and the second stage is segmentation. Normalization involved 
probe-specific adjustments to remove intensity biases due to binding affinity differences and 
other artifacts [11]. Additional quality control pre-processing steps are also needed according to 
each individual platform-specific protocol.  Segmentation incorporated statistical methods to 
identify the exact regions of the genome, on a patient level basis, where the relative copy number 
value is greater or less than the observed diploid value coming from the control/normal DNA 
sample. Segmentation is implemented under the observation that, within an individual sample, 
adjacent positions in the genome are likely to have the same underlying copy number [22, 23]. 
Therefore, segmentation groups the genome into regions that share the same DNA copy number, 
and identifies the region/location of DNA copy number changes. The two main segmentation 
methods selected for this research was the circular binary segmentation (CBS) tool by Olshen et 
al. 2004, and the sup-Wald identification of copy changes in DNA (SWITCHdna) tool by 
Weigman et al. 2011 [23, 24]. Both segmentation tools incorporated maximum likelihood 
statistics to test for significant breakpoints separating neighboring regions (i.e. change-points) 
and to apply their test procedures iteratively until no more changes are detected [23, 24]. 
 
Molecular Intrinsic Subtypes of Breast Cancer 
 Genomic studies using microarray technology have identified “intrinsic” human breast  
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cancer subtypes through differential gene expression, resulting in the PAM50 [25] and Claudin-
low predictors [26]. These gene expression defined subtypes include the Basal-like (typically 
triple-negative), Claudin-low, HER2-enriched, Luminal A, Luminal B and a subgroup of normal-
like samples (some tumors and all true normals). Furthermore, these breast cancer subtypes 
demonstrated prognostic value as patients with Basal-like, HER2-enriched and Claudin-low 
tumors exhibited a worse prognosis compared to patients with Luminal (in particular Luminal A) 
tumors [26]. Additionally, there are specific gene expression features and frequently copy 
number altered regions of the genome observed for each intrinsic subtype, thus highlighting the 
heterogeneity of breast cancers. The genomic features of the intrinsic subtypes will be described 
further below, with an emphasis on the DNA copy number landscape, which has been a constant 
focus of my thesis research. 
 Basal-like Subtype. The Basal-like subtype represents roughly 10-20% of all breast 
tumors [27]. The Basal-like subtype disproportionally affects African American women, is very 
prevalent among younger African American women (27%), and also demonstrates higher 
mortality rates [28, 29]. The majority of Basal-like tumors lack expression of the hormone 
receptors (ER and PR) or the amplification and/or over-expression of HER2, and therefore are 
commonly referred to as “triple-negative” (ER-/PR-/HER2-) [27]. Lacking the standard targets 
of drug therapy, these tumors often only have chemotherapy options and demonstrat high risk of 
recurrence and disease progression. Therefore, not surprisingly, Basal-like patients also 
demonstrate a worse overall and relapse free survival in the absence of systemic therapies [26, 
30, 31].  
 These tumors were initially referred to as Basal-like due to the unique expression of basal 
epithelial genes including cytokertain 5, 6, and 17 [31, 32]. Additionally, these tumors are highly 
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proliferative, demonstrating high expression of many cell cycle regulated genes and other 
markers of proliferations (i.e. proliferation index and the immunohistochemical marker Ki-67) 
[27, 33]. The high proliferative nature of Basal-like tumors is partially due to the lack of RB1 
protein function, a key regulator of the cell cycle [34]. Other important features of the Basal-like 
subtype include high occurrence of TP53 and BRCA1 mutations which, in combinations with 
RB1 loss, leads to high aneuploidy and high level of genomic instability [24, 27, 35]. Regions of 
previously observed high frequent CNAs in the Basal-like subtype include copy number losses at 
4q, 5q and copy number gains at 1q, 6p, 8q and 10p (Figure 1.1a) [24, 36]. 
 Claudin-Low Subtype. The Claudin-low subtype is the newest identified subtype, 
occurring in 5-7% of all breast cancers [26]. Claudin-low tumors also demonstrate poor 
prognosis representing an intermediate time of disease-free survival; better than the HER2-
enriched and Basal-like subtypes but worse than Luminal A and normal-like patients [26, 37]. 
The immunohistochemical definitions of the Claudin-low subtype are consistent with the  “triple-
negative” characteristics of Basal-like tumors. However, Claudin-low tumors lack the hallmark 
basal expression features, such as high expression of basal keratins and proliferation genes. 
 The subtype was named “Claudin-low” based on the unique lack of expression of the 
claudin family of genes. Specifically, the expression of the epithelial cell-cell adhesion genes 
claudin 3, claudin 4, and claudin 7 are all significantly lower in these breast tumors [26, 27, 28]. 
In addition, Claudin-low tumors lack the E-cadherin protein, an epithelial cell interaction protein 
involved in tight junctions [26, 27, 28]. Recently, Claudin-low tumors have been classified as 
having an intense immune cell infiltrate, with high expression of immune system response genes 
including CD4, CD79b and CD14 [26, 38]. Other characteristics of Claudin-low tumors include 
low expression of luminal cell surface markers, and enrichment of breast stem cell and epithelial-
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mesenchymal transition features [26, 38]. Regions of previously observed high frequent CNAs 
include copy number gains at 7p, 8q, and copy number losses at 8p (Figure 1.1c) [37]. 
 HER2-enriched Subtype. The HER2-enriched subtype is characterized by high 
expression of several genes on the ERBB2 (commonly known as HER2) amplicon at 17q22.24, 
which is the region that includes HER2 and GRB7 [31].  HER2 encodes for a cell surface protein 
with tyrosine kinase receptor activity, that activates signal transduction pathways involved in 
multiple cellular functions ranging from cell division, migration, adhesion, differentiation and 
apoptosis [39]. The subtype was named based on the observation that most samples within this 
subtype were clinically HER2 positive (HER2+) [38]. Clinically HER2+ tumors represent 15-
20% of all tumors, however, not all clinically HER2+ tumors fall within the HER2-enriched 
subtype, and not all HER2-enriched subtype tumors are HER2 amplified. The clinically HER2+ 
tumors that fall within the HER2-enriched subtype versus the Luminal subtypes are separated 
predominantly by ER status [40]. Specifically, 30-40% of HER2-enriched tumors are ER 
positive (ER+), meanwhile the majority lack the expression of ER (i.e. ER negative, ER-) [27].  
 Along with the Basal-like subtype tumors, HER2-enriched patients also demonstrate a 
significantly shorter overall and relapse free survival prognosis [31], which is likely due to 
deregulation of the ERBB signaling network [39]. However, amplification and/or overexpression 
of HER2 are associated with benefiting from trastuzumab treatment (an antibody targeting 
HER2) [41], with this targeting agent showing large improvements in patient outcomes.  In 
addition, HER2-enriched tumors show high genomic instability with frequent copy number gains 
at 1q, 8q, 17q, and copy number losses at 8p (Figure 1.1b) [36, 40].  
 Luminal Breast Cancers. Luminal breast tumors are characterized by high gene and 
protein expression of the luminal signature, which includes the Estrogen Receptor (ESR1), the 
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Progesterone Receptor (PGR), FOXA1 and BCL2 [30, 40]. From an immunohistochemical stand 
point, Luminal tumors are generally ER+ and/or PR+ [29].  Additional profiling studies 
highlighted two distinct subtypes within Luminal tumors, separating into Luminal A and 
Luminal B [30]. In a given population, Luminal A tumors tend to occur more often then Luminal 
B tumors (roughly 2/3 versus 1/3 frequency). The Luminal B subtype is distinctly separate from 
the Luminal A tumors by exhibiting lower expression of the luminal signature and higher 
expression of proliferation-related genes including MKI67, BIRC5, CCNB1 and MBL2 [33, 42]. 
Highly proliferative Luminal tumors have worst prognosis and poor response to standard 
therapies [43]. Consequently, Luminal A tumors demonstrate a more favorable survival outcome, 
living longer before developing metastatic disease [30].  
 Luminal tumors are also heterogeneous within the mutation and copy number landscapes. 
PIK3CA and TP53 genes are frequently mutated within both Luminal subtypes. However, 
Luminal A tumors demonstrate the largest set of recurrently mutated genes including GATA3, 
CDH1, MAP3K1 and FOXA1 [40]. Regions of previously observed high frequent CNAs within 
Luminal A tumors include copy number gains at 16p (Figure 1.1d), whereas, Luminal B tumors 
demonstrate copy number gains at 17q (Figure 1.1e) [36, 44].  Interestingly, both Luminal 
subtypes share a highly frequent copy number loss at 16q [44] (Figure 1.1d and Figure 1.1e).  
 
Conservation Based Approach Using Genetically Engineered Mouse Models 
 In science, the word “conservation” can have many meanings depending on the context. 
For an artist, conservation might refer to the restoration, protection and/or care of cultural 
heritage. For a mathematician, conservation might refer to a quantity that does not change over 
time. Consequentially, the word “conservation” may lead to a variety of hypotheses within 
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science. However, the underline concept of conservation is the same throughout science, and that 
is the preservation of some important feature(s).  
 Cancer progression is an evolutionary process driven by somatic cell factors [45].  One 
such factor in tumor progression is the acquisition of mutations in oncogenes and tumor 
suppressor genes [45], which can occur in the form of single nucleotide variants (SNV), or DNA 
CNAs (gains or losses of pieces of chromosomal DNA). We took an evolutionary approach to 
define “conservation”, and refer to conservation as the selection of shared breast tumor 
phenotypes in individuals from distinctly separate species (i.e. mice and humans). Understanding 
cancer development not only at the level of cells and tissue, but also cross-species can be an 
important feature in defining key carcinogenic events [46, 47].  
  Numerous genetically engineered mouse (GEM) mammary models are available that 
were created to mimic specific genetic properties observed in human breast cancers [48–50]. 
Incorporating GEM models provide an ability to study the interaction of different cell types and 
other physiological functions that are not represented in tissue culture cell analyses. However, 
certain caveats are included in murine to human comparative studies such as species-specific 
pathway differences and physiology differences [47].  However, the increase in available GEM 
mammary models and the advancement of gene expression profiling technologies provides an 
unique ability to group GEM mammary models together that share distinct gene expression 
patterns with human tumors. As a result, large combined human and murine gene expression-
based studies have identified gene expression features within mouse mammary model groups 
that are also observed in a specific human breast cancer subtype [49, 50]. However, on the gene 
expression level, there is not a single mouse mammary model that completely covers the 
complexity of any individual breast cancer subtype [49, 50].  
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On a DNA copy number level, mouse mammary models are particularly interesting as 
these models were designed to represent specific genetic alterations found in human breast 
cancers. Popular targets of mouse mammary modeling include overexpression of HER2/ERBB2 
or MYC, and inactivation of BRCA1, RB or TP53 [51–53]. Interestingly, we hypothesize that if a 
selected genetic alteration occurs frequently in a human breast cancer subtype, and a 
corresponding mouse mammary model is made with the same frequent genetic alteration, and if 
both then shares the same defining gene-expression features, this would be suggestive of 
causation of that subtype and a “conserved” genetic event. As a result, conserved alterations 
likely represent regions of importance in tumor progression, and the identification of these 
regions would be helpful to the scientific community. 
 Overlapping of CNAs across human and murine genomes created unique computational 
challenges. The first challenge was due to the inability to directly compare intensity values cross-
species from different copy number array technologies [11, 54]. To circumvent this challenge, 
individual significance tests are applied independently within a species/platform, and then only 
normalized values compared. Another challenge occurred due to variability in copy number 
segment sizes, and the differences in genetic annotation cross-species [23, 54]. To address this 
challenge, we initially increased the complexity from segments to gene level, with the 
observation that genes are the underlining target of an alteration and therefore are a more 
unambiguous cross-species. Next, given that blocks of synteny between human and murine 
genome may span multiple copy number segments, and given that a copy number altered 
segment many encompass numerous genes, we used the list of overlapping syntenic regions and 
the genes within them as the link. Using this overlapping gene list provided a straightforward 
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way to remap the murine genome in human order, with the caveat that mouse to human 
orthologues represent roughly 85% of all human genes [55].  
 
Research Introduction 
 In order to address the key topics discussed above, my thesis work highlighted the 
computational analyses and bioinformatics tools necessary to characterize CNAs in breast 
cancer. The studies in Chapter 2 and Chapter 3 utilized copy number and gene expression data to 
define drivers of CNAs in highly recurrent regions of copy number alterations. In addition, the 
studies in Chapter 2 and Chapter 3 also utilized functional data from RNAi screens to identify 
CNAs harboring genes essential for proliferation; thus representing novel integrated 
computational analyses utilizing multiple genomic data types, both quantitative and functional. 
 In Chapter 2, we characterized over 600 human tumors and 70 mouse mammary models 
of breast cancer to provide the largest human-to-mouse mammary dataset to date, which 
identified key human-to-mouse conserved copy number features. In addition, we demonstrated 
the usefulness of a new tool that can identify shared copy number features cross-species 
(SWITCHdna). Furthermore, we provided a resource for human to murine (and vice versa) 
cancer-related projects that can guide model selection during preclinical study designs. In 
Chapter 3, gene-expression based pathway activity was integrated with DNA copy number 
analyses to identify the impact of copy number regions with altered signaling pathway in 
tumorigenesis. Specifically, patterns of oncogenic signaling essential for cell proliferation were 
correlated with CNAs observed in highly proliferative luminal breast tumors.  
 In Chapter 4, the focus turns to the examination of another role CNAs play in the clinical 
setting, specifically when tumor DNA is used as the source of genomic DNA to make treatment 
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decisions. In this chapter, CNAs in tumors resulted in inaccurate genotype calls at a gene that is a 
marker of tamoxifen response. Throughout all this work, we highlighted the importance of 
understanding CNAs in both the laboratory and clinical setting and laid the foundation for how 
to integrate copy number data with other genomics data to determine subtype-specific drivers of 
tumorigenesis in breast cancer. !!!!!!!!!!!!!!!!!!!!!
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FIGURES 
 
 
Figure 1.1 Copy number frequency plots from SWITCHplus. Segments of copy number gains 
are plotted above the x-axis in red and segments of copy number loss plotted below the x-axis in 
green. The frequency of alterations in each subtype is indicated on the y-axis from 0-100%. a 
Basal-like, b Her2-enriched, c Claudin-low, d Luminal A e Luminal B copy number landscapes. 
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CHAPTER 2 
CROSS-SPECIES DNA COPY NUMBER ANALYSES IDENTIFIES MULTIPLE 1q21–q23 
SUBTYPE-SPECIFIC DRIVERS OF BREAST CANCER 
 
 
 A large number of DNA copy number alterations (CNAs) exist in human breast cancers, 
and thus characterizing the most frequent CNAs is key to advancing therapeutics because it is 
likely that these regions contain breast tumor ‘drivers’ (i.e. cancer causal genes). This study aims 
to characterize the genomic landscape of breast cancer CNAs and identify potential subtype-
specific drivers using a large set of human breast tumors and genetically engineered mouse 
(GEM) mammary tumors. Using a novel method called SWITCHplus, we identified subtype-
specific DNA CNAs occurring at a 15% or greater frequency, which excluded many well-known 
breast cancer related drivers such as amplification of ERBB2, and deletions of TP53 and RB1. A 
comparison of CNAs between mouse and human breast tumors identified regions with shared 
subtype-specific CNAs. Additional criteria that included gene expression-to-copy number 
correlation, a DawnRank network analysis, and RNA interference functional studies highlighted 
candidate driver genes that fulfilled these multiple criteria. Numerous regions of shared CNAs 
were observed between human breast tumors and GEM mammary tumor models that shared 
similar gene expression features. Specifically, we identified chromosome 1q21-23 as a Basal-like 
subtype enriched region with multiple potential driver genes including PI4KB, SHC1, and 
NCSTN. This step-wise computational approach based on a cross-species comparison is 
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applicable to any tumor type for which sufficient human and model system DNA copy number 
data exists, and in this instance, highlights that a single region of amplification may in fact 
harbor multiple driver genes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! *&!
INTRODUCTION 
Breast cancer is a heterogeneous disease that is characterized by distinct histological 
forms, genetic alterations, and patient outcomes [1–6]. Consistent with these observations, 
differential gene expression can distinguish molecular subtypes that separates breast cancer into 
distinct groups including Basal-like, Claudin-low, HER2-enriched, Luminal A, and Luminal B 
subtypes [2–4, 7–9]. These so called “intrinsic subtypes” are predictive of relapse-free survival, 
overall survival and responsiveness to treatment [7–11]. Previous work highlighted numerous 
somatic mutations [12] and DNA CNAs [13] that are linked to specific intrinsic subtypes, 
suggesting that these genetic events may be causative of these subtypes. Beyond a few well-
known drivers, the identification of genetic drivers present in many of these recurrent regions of 
DNA copy number change remains to be determined. Specifically, numerous copy number 
alterations are located on chromosome 1 and occur at high frequency among various cancer types 
including breast and liver [12, 14]. In breast cancer, copy number loss frequently occurs at 1p 
while copy number gains are frequent at 1q [13]. Furthermore, copy number gains at 1q often 
encompass the majority of the 1q arm, which include hundreds of genes. 
To identify additional genetic drivers of breast cancer in common regions of 
amplification, we have taken a cross-species conservation approach based upon the hypothesis 
that important etiological events in breast tumors will occur both in human breast cancers and 
mouse mammary tumor models. Through combined DNA copy number analyses of human 
breast tumors and multiple genetically engineered mouse (GEM) mammary tumor models, we 
identified 662 copy number alteration (CNA) regions conserved between these two species. Our 
ultimate selection strategy also incorporated gene expression data, an RNAi screen, and a 
network analysis to focus the list to the most likely driver genes within CNAs. Furthermore, 
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using published functional studies, we provide new insights on the potential implications of 
Basal-like tumor-specific chromosome 1 drivers, some of which are therapeutically targetable. 
 
MATERIALS AND METHODS 
 Breast cancer tumor datasets. For these comparative studies, two human datasets and 
one mouse dataset were used that contained both gene expression and DNA copy number data 
(Table 2.1). The two human datasets were: (1) tumors collected at the University of North 
Carolina at Chapel Hill and the Oslo University Hospital, Radiumhospitalet, Norway (“UNC”, 
n=159, GSE52173), and (2) The Cancer Genome Atlas (TCGA) Project dataset [12] (“TCGA”, 
n=485).  The third dataset contained tumors from numerous mouse mammary tumor models 
including GEM mammary models with inactivation of TP53, BRCA1, BRG1, and over-
expression of cMYC, HER2/ERBB2/Neu, PyMT and WNT1 (“mouse”, n = 73, GSE52173). The 
publically available level 3 segmented copy number data for the TCGA dataset was downloaded 
through the TCGA data portal and the published PAM50 subtype calls were used [12]. 
Demographic and clinical characteristics of the UNC tumors, and an extended methods section 
are provided in the online version of the paper. 
 Cross-species assessment of subtype-specific changes in genomic DNA copy number. 
To identify subtype-specific CNAs from segmentation data generated by the various copy 
number array platforms, we produced an add-on script to the SWITCHdna method of DNA copy 
number change point detection [13]. We created an R suite of functions called SWITCHplus, 
which can identify segments of the genome with copy number changes specific for a user 
determined set of tumors, thus providing a supervised method for analyzing copy number data. 
SWITCHplus is provided as a source script in R and available for download at: 
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https://genome.unc.edu/SWITCHplus/. Note, that we did not perform multiple hypothesis testing 
corrections as we chose alternative biologically based filtering criteria (Figure 2.1) based upon 
cross-species conservation. 
 Computational analysis of candidate driver genes within conserved CNAs. In order 
to identify putative driver alterations within regions of copy number gains or losses, we began 
with all the conserved CNAs with a subtype segment frequency of 15% or greater. To distinguish 
putative drivers from passengers, three further criteria were used. We first identified genes 
within a CNA that demonstrate concordance between the DNA and RNA expression.  The 
second criterion filtered for conserved CNAs that contained genes with a breast cell line RNAi-
associated phenotype as published in the Solimini et al. 2012 RNAi screen on Human Mammary 
Epithelial Cells [15]. The third criterion was to identify top ranking genes when scored using 
DawnRank [16]. By combining all these features together, we further decrease the false positive 
genes by filtering out genes without functional implications (Table 2.2).   
 
RESULTS 
Subtype-specific breast cancer copy number landscapes 
 In order to identify both known and novel genetic drivers of breast cancer on the DNA 
copy number level, we developed a multi-step and multi-platform computational strategy (Figure 
2.1). This strategy is predicated on using a “cross-species” comparative genomics approach 
where we searched for spontaneous copy number events across two different species (human and 
mouse). For this study, we created a new murine genomic resource of 73 mammary tumors 
profiled by both gene expression and DNA copy number microarray data (GSE52173); this new 
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resource complements our human data set that contains 644 human breast tumors that have both 
gene expression and DNA copy number data (GSE52173 and https://tcga-data.nci.nih.gov/tcga). 
We began by using gene expression data to identify subtypes, separately for human tumor 
samples and GEM mammary models. For clarity, we refer to the classification of mouse tumors 
as “groups” to distinguish them from human classes that are termed “subtypes”. Using the 
PAM50 [8] algorithm and the Claudin-low predictor [9] we assigned each of the human tumor 
samples within the dataset to a specific intrinsic breast cancer subtype (Table 2.1). However, 
since there is no established expression-based classifier for mouse mammary tumors, we 
performed a supervised hierarchical cluster analysis of the murine mRNA expression data using 
the Herschkowitz et al. 2007 intrinsic mouse list of 866 genes. SigClust [17] analysis was used to 
identify 7 significant mouse groups (Figure 2.2), which were given an unique group name based 
on the majority mouse model contributor in that group (i.e. Myc, Neu/PyMT, Wnt1, C3Tag, 
Mixed, p53null-Basal, and p53null-Luminal). The “Mixed” mouse group lacked a single 
dominant mouse model contributor, however, this group was comprised of mouse tumors that all 
demonstrate the previously described Claudin-low gene expression features [18, 19], and hence 
forth this mouse group is referred to as “ClaudinLow”.  
 To identify subtype-specific, and mouse group-specific regions of DNA copy number 
gains and/or losses we developed a new bioinformatics visualization tool called SWITCHplus. 
Applying this tool to the mouse dataset identified group-specific DNA copy number changes for 
each of the seven expression-defined groups (Figure 2.3). These results suggest that most mouse 
groups are characterized by numerous DNA copy number changes, many of which are specific to 
a given model/group (source data available in the online version of the paper). However, by 
comparing the copy number landscape between mouse groups, we also identified CNAs that 
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were present in multiple models (Figure 2.3), which can be considered common CNAs of murine 
mammary oncogenesis. Therefore, these data support the notion that common spontaneous 
events may occur within different GEM mammary models irrespective of the initiating genetic 
event (i.e. transgene). Consistent with previous work, we identified multiple GEM mammary 
p53null groups based on gene expression patterns [18, 19]. Interestingly, these p53null groups 
demonstrated not only differences in mRNA expression patterns, but also exhibited differences 
in the DNA copy number landscapes (Figures 2.3c and 2.3d). Additionally, we noticed that the 
p53null-Luminal, p53null-Basal and C3-Tag groups contained more group-specific CNAs than 
any of the other mouse groups (source data available in the online version of the paper); this 
observation is likely due to the loss of TP53 in these three groups. On average, each mouse 
group exhibited nearly twice the number of group-specific copy number gains versus losses. 
We next analyzed the human DNA copy number landscape in the combined UNC/TCGA 
breast cancer dataset (Figure 2.4). Our results, not surprisingly, were consistent with previous 
publications [6, 12, 13]. For example, our analyses confirmed previously identified breast cancer 
copy number gains of 8q that is common and present irrespective of breast cancer subtype, as 
well as a number of subtype-specific CNAs. For instance, we again identified Basal-like-specific 
DNA copy number losses at 4q, 5q and gains of 10p; Luminal A-specific copy number gains at 
16p; Luminal B-specific copy number gains at 17q; and a Luminal-associated (encompassing 
both Luminal A and Luminal B) copy number loss at 16q (Figure 2.4 and source data available 
online) [6, 12, 13, 20, 21]. The HER2-enriched subtype contained few subtype-specific CNAs, 
noting that the HER2/ERBB2 amplicon was not a HER2-enriched subtype specific copy number 
gain event as it also occurred in many Luminal tumors. Additionally, the Basal-like subtype 
contained the highest number of subtype-specific CNAs (source data available online). In 
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contrast to what was observed in the mouse groups, human tumors on average demonstrated 
more frequent subtype-specific regions of copy number loss compared to copy number gains 
(source data available online). 
 
Comparisons of copy number landscapes of mouse and human breast tumors 
 The extent to which mouse models of breast cancer recapitulate human phenotypes has 
been examined at the gene expression level [18–20], as well as on the copy number level, albeit 
only in a much smaller subset of these data [20]. We examined sub-chromosomal events and 
compared human subtype-specific copy number landscape plots to mouse group-specific 
landscape plots and identified shared cross-species CNAs events (after re-ordering the mouse 
chromosomal landscape into human chromosome order). We first selected for “conserved 
regions”, which were DNA segments/regions that were altered at high frequency (> 15%) and in 
the same direction (i.e. amplified or lost) in both human and mouse copy number landscapes. 
Applying this selection criterion reduced the search space for potential subtype-specific drivers 
more than 2-fold, leaving a total of 662 conserved regions when all mouse groups and human 
subtypes were considered (Figure 2.5 and source data available online). 
In comparison amongst subtypes, the Claudin-low subtype had the fewest number of 
conserved regions (and the fewest CNAs overall) (source data available online). Conversely, the 
Basal-like subtype contained the most conserved CNAs; however, this may be due to the fact 
that the Basal-like subtype also contained the most subtype-specific CNAs (source data available 
online). Consistent with a previous publication [20], shared Basal-like-specific and murine 
p53null-Basal-specific regions of DNA copy number loss was observed spanning human 4q31–
q35.2 and encompassing INPP4B, and also spanning 14q22.1-23.1 (source data available online). 
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By comparing shared sub-chromosomal CNAs between the human Basal-like subtype and all 
mouse groups, we noted that the C3-Tag mouse group contained the most human Basal-like-
specific copy number amplified regions, while the p53null-Basal mouse group contained the 
most human Basal-like-specific copy number loss regions (source data available online). Both of 
these mouse models were previously shown to have the Basal-like tumor gene expression 
phenotypes [18, 20], therefore, for this study, we largely focused on copy number commonalities 
between human Basal-like tumors and these two mouse groups. 
 
Identification of Basal-like tumor chromosome 1 amplification driver genes 
Across all breast tumors, amplification of human chromosome 1q was the most frequent 
copy number altered event (not depicted). However, as can be seen in Figures 2.4 and 2.5, the 
“shape” of the chromosome 1 amplification varies by subtype, with the subtype-enriched 
amplification regions being identified within this largest of human chromosome arms. Among 
the 662 conserved regions identified across the genome, chromosome 1 harbored 18% of all 
conserved CNAs (source data available online). Focusing on chromosome 1, we determined that 
chromosome 1q harbored more than twice the number of conserved segments when compared to 
the 1p arm (source data available online). Of particular note, a number of 1q amplified regions 
that were identified as human Basal-like-specific were also altered in the mouse C3-Tag and/or 
p53null groups (Figure 2.6 and Appendix 1); thus our results indicate that this region of human 
chromosome 1q21-23 is being repeatedly selected for in both mouse and human Basal-like breast 
cancers.  
In order to identify the driver(s) present on chromosome 1, we next applied our filtering 
criteria outlined in Figure 2.1. Of the 120 chromosome 1 conserved CNAs, 79 contained at least 
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one gene that showed DNA to RNA concordance (Appendix 2); 25 CNAs contained at least one 
RNAi identified essential gene (Table 2.3), and 20 CNAs contained genes showing DNA to 
RNA concordance and a RNAi identified essential gene (Table 2.4). Interestingly, all 20 CNAs 
were copy number gained segments, even among the 1p CNAs (Table 2.4).  
To further study the biology of the conserved chromosome 1 genes, we performed a 
cohort based DawnRank [16] analysis using genes from human chromosome 1. DawnRank uses 
gene-gene interaction networks to measure the impact of genomic alterations on the differential 
gene expression of downstream genes in the network. Then, DawnRank scores (as previously 
described [16]) the level of perturbation on the gene interaction network caused by the alteration 
(either amplification or deletion) of the gene of interest. We selected human chromosome 1 gene 
blocks with shared synteny with the mouse genome for the DawnRank analysis. There were 7 
such gene blocks, totaling 1509 genes (source data available online). Using the chromosome 1 
syntenic regions, we identified 44 chromosome 1 genes that represented the top 5% DawnRank 
scores using DNA copy number changes as the input “mutation” features along with the gene 
expression for each human tumor sample (Appendix 3). The 44 DawnRank genes mapped to 9 
copy number gained segments, which also harbored genes with DNA to RNA concordance, or an 
RNAi identified essential gene (Table 2.4). Within the 9 CNAs, encompassing a total of 182 
potential genes, only 3 genes met all four filtering criteria of 1) subtype-specific CNA, 2) DNA 
to RNA concordance, 3) a RNAi “GO” gene, and 4) a DawnRank hit: these genes were 
phosphatidylinositol 4-kinase (PI4KB), src homology 2 domain-containing (SHC1), and nicastrin 
(NCSTN) (Figure 2.6 and Table 2.4). 
 The three chromosome 1 potential driving genes span 1q21-q23 and are altered with an 
average segment subtype frequency of 47% (Table 2.4). Interestingly, PI4KB and SHC1 span 
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1q21, falling less than the average Basal-like subtype segment length apart (Figure 2.6), thus 
suggesting that on chromosome 1q21-23 multiple target genes lie within a single amplicon. 
Furthermore, SHC1 is in a subtype-specific high frequency altered segment among Basal-like 
tumors only (Figure 2.6 and Appendix 1), while NCSTN and PI4KB CNAs appeared across 
multiple subtypes, passing the significance threshold in the Basal-like and Luminal A subtypes 
(Appendix 2). However, NCSTN and PI4KB also passed the significance threshold for the 
p53null-Luminal, p53null-Basal, and C3-Tag mouse groups (Appendix 1), the last two of which 
are models linked to human Basal-like disease as determined in previous gene expression 
comparative studies [18, 19]. 
 
Notch pathway features in 1q21-23 amplified Basal-like breast cancers ! Numerous studies have implicated the Notch signaling pathway in Basal-like breast 
and/or Triple-Negative Breast Cancers [22, 23]. Importantly, numerous studies on the functional 
role of NCSTN have already been performed [24–26]. To evaluate the effect of 1q21-23/NCSTN 
amplification, we first examined the DawnRank network space around NCSTN and noted that 
when NCSTN was amplified NOTCH1, NOTCH2, and NOTCH3 were also more highly 
expressed (Figure 2.7). In addition, NCSTN is one of three components of the gamma-secretase 
complex, a protein complex that cleaves and activates Notch receptors. Two other gamma-
secretase complex members, namely APH1A and PSEN2, were also both altered within the 
network (Figure 2.7), and were also higher in NCSTN amplified samples versus not amplified 
(Figure 2.8a). Also, APH1A and PSEN2 are physically located on human chromosome 1q21.2 
and 1q42, and are often co-amplified along with NCSTN (although PSEN2 is not within a Basal-
like-specific CNA). Thus, three components of the gamma-secretase complex are often co-
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amplified together, and more highly expressed, and the NCSTN/Notch Network is perturbed in 
these NCSTN amplified tumors. Following up on these network findings, NCSTN amplification 
was also correlated with higher NOTCH1 and NOTCH3 mRNA levels (Supplemental Figure 4b), 
with this feature showing an even greater difference when examined just amongst Basal-like 
breast cancers (Figure 2.8c). As expected from previous work, Basal-like tumors as a whole 
exhibited significantly lower LFNG expression (i.e. a negative regulator of Notch signaling) 
along with significantly higher expression of NOTCH1, NCSTN, APH1A, MYC, and HEY2 
mRNAs (Figure 2.9), the latter two of which are thought to be a targets of activated Notch-
pathway.  
 
DISCUSSION 
 In breast cancer, there are many copy number gains and losses, a few of which like 
amplification of ERBB2, are of known clinical and biological significance. Over the years, many 
of these CNAs have been studied and candidate genes identified [12, 13, 27–30], but there are 
still many regions for which the genetic drivers remain unknown. The simultaneous analysis of 
DNA copy number change in both human and mouse tumors, and their corresponding gene 
expression patterns, provides for a biologically meaningful way to identify important regions of 
CNAs. The basic hypothesis being that a CNA found to spontaneously occur in two different 
mammalian species breast cancers is being repeatedly selected for and must therefore contain an 
important tumor causing gene(s). 
Although many studies have identified frequent CNAs within groups of human breast 
tumors [13, 21], most do not functionally narrow down the candidate genes within a specific 
segment. In addition to the mere presence of a highly frequent CNAs being identified across 
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species, we took a biologically based approach to refine the list of genes within a given segment 
into a subset of candidate driver genes. These analyses prompted the development of a new a 
bioinformatics tool (SWITCHplus) to identify and highlight subtype-specific DNA copy number 
events using a visual display in a user-friendly format. Using this tool and a systematic data-
mining schema that includes identifying regions that show: 1) shared DNA CNAs cross-species, 
2) concordance between mRNA expression and relative DNA copy number value, 3) functional 
effects in a genome-wide RNAi screen, and 4) functional effects in a network analysis (i.e. 
DawnRank), we identified a limited number of CNAs that harbored potential breast cancer driver 
genes. From these analyses, we identified human chromosome 1q21-23 as a region of 
amplification consistently present in human and mouse Basal-like tumors, and which contains at 
least three potential driver genes (Figure 2.6). 
 The first of these three genes, PI4KB encodes for a lipid kinase member of the 
phosphoinositide signaling pathway. The phosphoinositide signaling system regulates cell 
migration [31–33], proliferation [31–33], and activation of this signaling pathway is observed in 
many aggressive tumors [33–35]. Specifically, phosphatidylinositol 4-phosphate is utilized by 
phosphoinositide kinases, such as PI3KCA, to signal to downstream protein kinase targets 
including AKT and PDK1 [33, 35, 36]. In the 2012 TCGA publication on breast cancer, it was 
noted that Basal-like cancers showed high activity of the PIK3CA/AKT pathway, and that these 
tumors tended to show few PIK3CA mutations, but frequent loss of PTEN and/or INPP4B 
(negative regulators of the pathway) and amplification of PIK3CA and AKT3 (positive regulators 
of the pathway) [12]. Here we show yet another positive regulator of the pathway is amplified in 
Basal-like cancers. 
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 SHC1 encodes for a member of the Shc family of adapter proteins. SHC1 is composed of 
multiple protein domains that can bind to multiple transmembrane receptors including 
phosphorylated insulin-like growth factor 1 receptor (IGF1R), and the platelet-derived growth 
factor receptor (PDGFR), thus potentially activating multiple pathways involved in cell 
proliferation and differentiation [37, 38]. Specifically, SHC1 is a key signaling mediator, and can 
act as a scaffold between an activated receptor and downstream signaling proteins [39]. In 
addition, growth factor signaling through PDGFR is known to occur in many TNBC [40], and 
thus SHC1 amplification may be contributing to these key signaling processes. 
 NCSTN encodes for a component of the gamma-secretase complex (GSC), which is a 
multi-protein complex that cleaves a number of transmembrane proteins to typically activate 
their functions [41, 42]; the GSC targets include Notch 1-4, ErBB4, CD44 and E-cadherin [24, 
41, 42]. Importantly, Hu et al. 2002 demonstrated, in Drosophila, that NCSTN provides 
structural support and is required for GSC cleavage of Notch receptor [43].  In our data, when 
Basal-like tumors were examined, those with copy number gains at NCSTN showed 1) 
perturbation/activation of the Notch pathway via the DawnRank network analysis (Figure 2.7), 
2) significantly higher expression of NOTCH1 and NOTCH3 (Figure 2.8c), and 3) high 
expression of other markers of the Notch pathway (Figure 2.8d). Further support for Notch-
pathway importance comes from previous mouse model experiments where genetic inactivation 
of a negative regulator of Notch signaling (i.e. lunatic fringe) resulted in Basal-like mammary 
tumors [22]. Interestingly, Notch activity is also higher in Basal-like breast cancer cell lines 
compared with luminal breast cancer cell lines [44]. In vitro, by RNAi-mediated silencing of 
NCSTN in the TNBC cell-line MDA-MB-231, Filipovi et al. 2011 showed reduced transcription 
of Notch pathway targets, and a reduction in cell motility and invasion [41]. In total, these results 
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strongly suggest that activation of Notch-pathway signaling is occurring within Basal-like/TNBC 
tumors, and we now provide additional evidence for a mechanistic explanation for this in vivo.  
Other investigators using different computational approaches have also identified this 
region, but identified other genes (i.e. NIT1 and PVRL4) as potential drivers [45]. The observed 
differences in potential driver genes is mostly likely due to the “filtering criteria”, where we 
focused on species conservation, and they focused on somatic mutation targets. It is clear that a 
multitude of targets and drivers are present, and that 1q21-23 is a region that is the target of 
selection as opposed to any single gene being the target of selection. In conclusion, our work 
here provides an objective analysis path for identifying potential driver genes using a cross-
species computational approach, which can be applied to any tumor type for which sufficient 
mouse and human tumor data exist. 
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TABLES 
Table 2.1 Copy number array sample information of Human and Mouse tumors 
 
Subtype Number of Samples Total 
Basal-Like UNC: 54 TCGA: 89 143 
Claudin-Low UNC: 20 TCGA: 8 28 
HER2-enriched UNC: 16 TCGA: 55 71 
Luminal A UNC: 35 TCGA: 213 248 
Luminal B UNC: 34 TCGA: 120 154 
 
Expression SigClust Group Number of Samples 
Wap Myc 10 
Neu/PyMT 11 
Wnt1 16 
C3Tag 8 
Mixed 6 
p53null-Basal 9 
p53null-Luminal 13 
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Table 2.2 Basal-specific pipeline segments count 
 
Pipeline Segment Count 
Stage 1: Basal-specific segments 1511 
Stage 2: Basal-specific segments with frequency at least 15% 1067 
Stage 3: Basal-specific conserved segments with frequency at least 15% 429 
Stage 4: Basal-specific conserved segments with RNAi screen genes & frequency 
at least 15% 104 
Stage 5: Basal-specific conserved segments showing DNA & RNA concordance in 
Human samples & frequency at least 15% 341 
Stage 6: Basal-specific conserved segments showing DNA & RNA concordance in 
Mouse Samples & frequency at least 15% 126 
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Table 2.3 Chromosome 1 subtype specific conserved CNAs with frequency >= 15 and genes 
found in RNAi screen 
 
Chr Start Stop % Genes in Segment CNA 
Mouse 
group-
specific 
CNA 
Solimini 
et al 2012 
GO/STO
P RNAi 
Subtype 
1 78405135 78535584 0.20 FUBP1 GAIN C3Tag FUBP1 Basal 
1 113655140 116683656 0.22 
RSBN1, BCL2L15, AP4B1, 
DCLRE1B, HIPK1, OLFML3, 
SYT6, TSHB, TSPAN2, NGF, 
CASQ2, NHLH2, SLC22A15 
GAIN C3Tag DCLRE1B, HIPK1 Basal 
1 145792064 150025833 0.50 BOLA1, SV2A, SF3B4, MTMR11, OTUD7B GAIN C3Tag SF3B4 LumA 
1 146101240 148205520 0.57 PRKAB2, FMO5, CHD1L, BCL9, ACP6 GAIN 
C3Tag, 
Myc PRKAB2 Basal 
1 149850351 149935164 0.59 
HIST2H2BE, HIST2H2AC, 
HIST2H2AB, BOLA1, SV2A, 
SF3B4, MTMR11 
GAIN C3Tag SF3B4 Basal 
1 150929687 151773763 0.62 
LASS2, ANXA9, FAM63A, 
PRUNE, BNIPL, CDC42SE1, 
MLLT11, GABPB2, SEMA6C, 
TNFAIP8L2, LYSMD1, 
SCNM1, TMOD4, VPS72, 
PIP5K1A, PI4KB, RFX5, 
PSMB4, POGZ, CGN, TUFT1, 
MIR554, SNX27, CELF3, 
MRPL9, TDRKH 
GAIN C3Tag 
GABPB2, 
PI4KB, 
PSMB4, 
TDRKH 
Basal 
1 151062957 151321770 0.50 
SEMA6C, TNFAIP8L2, 
LYSMD1, SCNM1, TMOD4, 
VPS72, PIP5K1A, PI4KB, 
RFX5 
GAIN C3Tag PI4KB LumA 
1 151321770 151409843 0.50 PSMB4 GAIN C3Tag PSMB4 LumA 
1 151659023 151789548 0.50 CELF3, MRPL9, TDRKH, LINGO4 GAIN 
ClaudinLo
w, C3Tag TDRKH LumA 
1 151880754 152292453 0.50 S100A10, S100A11, TCHH, RPTN, HRNR GAIN 
ClaudinLo
w, C3Tag RPTN LumA 
1 152067728 152208144 0.62 TCHH, RPTN, HRNR GAIN ClaudinLow, C3Tag RPTN Basal 
1 152233280 152643406 0.64 FLG2, CRNN, CRCT1, LCE3C, LCE3B, LCE3A GAIN C3Tag LCE3C Basal 
1 152447359 152617731 0.51 CRCT1, LCE3C, LCE3B, LCE3A GAIN C3Tag LCE3C LumA 
1 152661380 153346263 0.64 
KPRP, LCE1F, LCE1E, 
LCE1C, LCE1B, LCE6A, 
SMCP, IVL, SPRR4, SPRR1A, 
SPRR3, SPRR1B, SPRR2D, 
SPRR2B, SPRR2E, SPRR2F, 
SPRR2G, LELP1, LOR, 
PGLYRP3, PGLYRP4 
GAIN C3Tag PGLYRP3 Basal 
1 153354347 153576396 0.64 S100A8, S100A7A, S100A6, S100A5, S100A4, S100A3 GAIN C3Tag S100A5 Basal 
1 153576396 154012535 0.63 
S100A16, S100A14, S100A13, 
C1orf77, SNAPIN, ILF2, 
NPR1, INTS3, SLC27A3, 
GATAD2B, DENND4B, 
SLC39A1, CREB3L4, JTB, 
JTB, RPS27 
GAIN C3Tag NPR1 Basal 
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Table 2.3 Chromosome 1 subtype specific conserved CNAs with frequency >= 15 and genes 
found in RNAi screen (Continued) 
 
Chr Start Stop % Subtype-Specific Genes in Segment CNA 
Mouse 
Group 
Solimini 
et al 2012 
GO/STO
P RNAi 
Subtype 
1 154270185 154318564 0.62 ATP8B2 GAIN C3Tag ATP8B2 Basal 
1 154807935 155175657 0.62 
PMVK, PYGO2, SHC1, 
CKS1B, FLAD1, LENEP, 
ZBTB7B, DCST2, DCST1, 
DPM3, KRTCAP2, TRIM46, 
MUC1, MIR92B 
GAIN C3Tag SHC1, TRIM46 Basal 
1 155936658 156321154 0.60 
SSR2, UBQLN4, RAB25, 
MEX3A, LMNA, SEMA4A, 
SLC25A44, PMF1, BGLAP, 
PAQR6, SMG5, TMEM79, 
CCT3, C1orf182 
GAIN C3Tag 
CCT3, 
C1ORF18
2 
Basal 
1 156321154 156545720 0.59 RHBG, MEF2D, IQGAP3 GAIN C3Tag RHBG Basal 
1 160043165 160439014 0.57 
KCNJ9, IGSF8, ATP1A2, 
ATP1A4, CASQ1, DCAF8, 
PEX19, COPA, SUMO1P3, 
NCSTN, NCSTN, NHLH1, 
VANGL2 
GAIN 
C3Tag, 
p53null_
Basal 
CASQ1, 
COPA, 
SUMO1P
3, 
NCSTN, 
NCSTN 
Basal 
1 160197660 160372346 0.51 PEX19, COPA, SUMO1P3, NCSTN, NCSTN, NHLH1 GAIN 
C3Tag, 
p53null_
Basal, 
p53null_
Luminal 
COPA, 
SUMO1P
3, 
NCSTN 
LumA 
1 160906176 163790065 0.18 
F11R, USF1, ARHGAP30, 
PVRL4, KLHDC9, NIT1, 
DEDD, DEDD, UFC1, PPOX, 
B4GALT3, ADAMTS4, 
NDUFS2, FCER1G, APOA2, 
TOMM40L, NR1I3, NR1I3, 
PCP4L1, MPZ, SDHC, 
C1orf192, FCGR2B, FCRLA, 
FCRLB, DUSP12, ATF6, 
OLFML2B, NOS1AP, MIR556, 
UHMK1, UAP1, DDR2, 
HSD17B7, RGS4, RGS5, NUF2 
GAIN p53null_Luminal 
F11R, 
TOMM40
L, NR1I3, 
FCGR2B, 
FCRLA 
Claudin 
1 182988016 184909056 0.18 
LAMC1, LAMC2, NMNAT2, 
SMG7, NCF2, ARPC5, RGL1, 
APOBEC4, GLT25D2, 
TSEN15, EDEM3 
GAIN p53null_Luminal GLT25D2 Claudin 
1 205333969 206253777 0.73 
LEMD1, MIR135B, CDK18, 
MFSD4, ELK4, SLC45A3, 
NUCKS1, RAB7L1, SLC41A1, 
PM20D1, SLC26A9, FAM72A, 
AVPR1B 
GAIN ClaudinLow CDK18 LumB 
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Table 2.4 Chromosome 1 conserved CNAs with frequency >= 15%, concordant with gene 
expression, RNAi identified essential gene, and top DawnRank score 
 
Chr Start Stop Seg Freq CNA 
Mouse 
Model 
Solimini 
et al 2012 
GO/STOP 
RNAi 
Concordant 
DNA/RNA Subtype 
Dawn
Rank ALL 3 
1 78405135 78535584 0.20 GAIN C3Tag FUBP1 FUBP1 Basal   
1 113655140 116683656 0.22 GAIN C3Tag DCLRE1B, HIPK1 
 RSBN1, BCL2L15, 
AP4B1, DCLRE1B, 
HIPK1, SLC22A15 
Basal NGF  
1 145792064 150025833 0.50 GAIN C3Tag SF3B4 BOLA1, SF3B4, MTMR11, OTUD7B LumA   
1 146101240 148205520 0.57 GAIN C3Tag, Myc PRKAB2 
PRKAB2, FMO5, 
CHD1L, BCL9, 
ACP6 
Basal   
1 149850351 149935164 0.59 GAIN C3Tag SF3B4 
HIST2H2AC, 
BOLA1, SF3B4, 
MTMR11 
Basal   
1 150929687 151773763 0.62 GAIN C3Tag 
GABPB2, 
PI4KB, 
PSMB4, 
TDRKH 
LASS2, FAM63A, 
PRUNE, BNIPL, 
CDC42SE1, 
GABPB2, SEMA6C, 
LYSMD1, SCNM1, 
TMOD4, VPS72, 
PIP5K1A, PI4KB, 
RFX5, PSMB4, 
POGZ, CGN, 
TUFT1, MIR554, 
SNX27, MRPL9, 
TDRKH 
Basal PI4KB PI4KB 
1 151062957 151321770 0.50 GAIN C3Tag PI4KB 
SEMA6C, LYSMD1, 
SCNM1, TMOD4, 
VPS72, PIP5K1A, 
PI4KB, RFX5 
LumA PI4KB PI4KB 
1 151321770 151409843 0.50 GAIN C3Tag PSMB4 PSMB4 LumA   
1 151659023 151789548 0.50 GAIN ClaudinLow, C3Tag TDRKH 
MRPL9, TDRKH, 
LINGO4 LumA   
1 151880754 152292453 0.50 GAIN ClaudinLow, C3Tag RPTN S100A10, S100A11 LumA   
1 153354347 153576396 0.64 GAIN C3Tag S100A5 S100A8, S100A6 Basal   
1 153576396 154012535 0.63 GAIN C3Tag NPR1 
S100A16, S100A14, 
S100A13, C1ORF77, 
SNAPIN, ILF2, 
INTS3, GATAD2B, 
DENND4B, 
SLC39A1, 
CREB3L4, JTB, 
RPS27 
Basal 
GATA
D2B, 
SNAPI
N 
 
 
 
 
 
 
 
! ,-!
Table 2.4 Chromosome 1 conserved CNAs with frequency >= 15%, concordant with gene 
expression, RNAi identified essential gene, and top DawnRank score (Continued) 
 
1 154807935 155175657 0.62 GAIN C3Tag SHC1, TRIM46 
PMVK, PYGO2, 
SHC1, CKS1B, 
FLAD1, ZBTB7B, 
DCST2, DCST1, 
DPM3, KRTCAP2, 
TRIM46, MUC1 
Basal SHC1 SHC1 
1 155936658 156321154 0.60 GAIN C3Tag 
CCT3, 
C1ORF18
2 
SSR2, UBQLN4, 
RAB25, MEX3A, 
LMNA, SEMA4A, 
SLC25A44, PMF1, 
BGLAP, PAQR6, 
SMG5, TMEM79, 
CCT3, C1ORF182 
Basal SMG5  
1 156321154 156545720 0.59 GAIN C3Tag RHBG MEF2D, IQGAP3 Basal   
1 160043165 160439014 0.57 GAIN 
C3Tag, 
p53null_B
asal 
CASQ1, 
COPA, 
SUMO1P
3, 
NCSTN, 
NCSTN 
IGSF8, DCAF8, 
PEX19, COPA, 
SUMO1P3, NCSTN, 
NHLH1, VANGL2 
Basal NCSTN 
NCST
N 
1 160197660 160372346 0.51 GAIN 
C3Tag, 
p53null_B
asal, 
p53null_L
uminal 
COPA, 
SUMO1P
3, 
NCSTN, 
NCSTN 
PEX19, COPA, 
SUMO1P3, NCSTN, 
NHLH1 
LumA NCSTN 
NCST
N 
1 160906176 163790065 0.18 GAIN p53null_Luminal 
F11R, 
TOMM40
L, NR1I3, 
NR1I3, 
FCGR2B, 
FCRLA 
F11R, USF1, 
PVRL4, KLHDC9, 
NIT1, DEDD, UFC1, 
PPOX, B4GALT3, 
ADAMTS4, 
NDUFS2, 
TOMM40L, NR1I3, 
PCP4L1, SDHC, 
C1ORF192, 
DUSP12, ATF6, 
NOS1AP, MIR556, 
UHMK1, UAP1, 
HSD17B7, NUF2 
Claudin 
DEDD
, 
F11R,  
FCER
1G, 
FCGR
2B 
F11R 
1 182988016 184909056 0.18 GAIN p53null_Luminal GLT25D2 
LAMC2, SMG7, 
ARPC5, TSEN15, 
EDEM3 
Claudin   
1 205333969 206253777 0.73 GAIN ClaudinLow CDK18 
CDK18, MFSD4, 
ELK4, SLC45A3, 
NUCKS1, RAB7L1, 
SLC41A1, FAM72A 
LumB   
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FIGURES 
 
Figure 2.1 Data-analysis pipeline to identify subtype-specific CNA candidate driver genes.  
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Figure 2.2 Supervised cluster of mouse gene expression data using an 866 intrinsic gene list. 
The cluster analysis identified 7 murine tumor subtypes, which were further used to supervise 
subsequent DNA copy number analyses. Each group is labeled according to the majority 
component mouse model within that group. 
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Figure 2.3 Copy number frequency plots from SWITCHplus showing mouse group-specific 
CNAs. Segments of group-specific copy number gains are plotted above the x-axis in red and 
segments of copy number loss plotted below the x-axis in green. Regions shaded gray indicate 
segments that are not group-specific or high frequent (greater than or equal to 15%). The 
frequency of alterations in each mouse group is indicated on the y-axis from 0-100%. a C3Tag, b 
Neu/PyMT, c p53null-Basal, d p53null-Luminal e Myc, f Wnt1, g ClaudinLow copy number 
landscapes. 
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Figure 2.4 Copy number frequency plots from SWITCHplus showing human subtype-specific 
CNAs. Segments of subtype-specific copy number gains are plotted above the x-axis in red and 
segments of copy number loss plotted below the x-axis in green. Regions shaded gray indicate 
segments that are not subtype-specific or high frequent (greater than or equal to 15%). The 
frequency of alterations in each subtype is indicated on the y-axis from 0-100%. a Basal-like, b 
Her2-enriched, c Claudin-low, d Luminal A e Luminal B copy number landscapes. 
! -%!
 
Figure 2.5 Copy number frequency plots from SWITCHplus showing conserved CNAs. 
Segments of copy number gains are plotted above the x-axis and segments of copy number loss 
plotted below the x-axis. Regions shaded gray indicate segments that are either not subtype-
specific, mouse group-specific or high frequent (greater than or equal to 15%). The conserved 
segments are colored according to the mouse model(s) in which they appear. The frequency of 
alterations in each subtype is indicated on the y-axis from 0-100%. a Basal-like, b Her2-
enriched, c Claudin-low, d Luminal A e Luminal B copy number landscapes. 
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Figure 2.6 Expanded view of a chromosome 1 Basal-like conserved copy number frequency 
plots for SWITCHplus.  Segments of copy number gains are plotted above the x-axis and 
segments of copy number loss plotted below the x-axis. Regions shaded gray indicate segments 
that are either not subtype-specific, mouse group-specific or high frequent (greater than or equal 
to 15%). The conserved segments are colored according to the mouse model(s) in which they 
appear. The frequency of alterations is indicated on the y-axis. b View of the genomic location of 
candidate chromosome 1 driver genes. Genes colored red are Basal-like subtype-specific or 
subtype-associated, demonstrate DNA and RNA concordance in human tumors and had a top 
DawnRank score; genes underlined are Basal-like subtype-specific or subtype-associated, 
demonstrate DNA and RNA concordance in human tumors and labeled as a growth enhancer and 
oncogene (“GO gene”) in the Solimini et al. 2012 RNAi screen on Human Mammary Epithelial 
Cells; the remaining genes surrounded by a box are additional potential drivers.  A color bar is 
placed above the genes conserved for a particular mouse group. 
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Figure 2.7 DawnRank identified NCSTN gene expression network 
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Figure 2.8 Box-and-whisker plots for expression of Notch signaling pathway targets. a APH1A 
and PSEN2 mRNA expression across all tumors with NCSTN amplification versus all other 
tumors without NCSTN amplification. b NOTCH1 and NOTCH3 mRNA expression across all 
tumors with NCSTN amplification versus all tumors without NCSTN amplification. c NOTCH1 
and NOTCH3 mRNA expression across all basal tumors with NCSTN amplification versus basal 
tumors without NCSTN amplification. d APH1A and PSEN2 mRNA expression across all basal 
tumors with NCSTN amplification versus basal tumors without NCSTN amplification. 
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Figure 2.9 Box-and-whisker plots of the mRNA expression of LFNG, NOTCH1, NCSTN, 
APH1A, MYC and HEY2 across breast cancer subtypes. 
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CHAPTER 3 
AN INTEGRATED GENOMICS APPROACH IDENTIFIES DRIVERS OF PROLIFERATION 
IN LUMINAL-SUBTYPE HUMAN BREAST CANCER 
 
 
 Elucidating the molecular drivers of human breast cancers requires a strategy that is 
capable of integrating multiple forms of data and an ability to interpret the functional 
consequences of a given genetic aberration. Here we present an integrated genomic strategy 
based on the use of gene expression signatures of oncogenic pathway activity (n = 52) as a 
framework to analyze DNA copy number alterations in combination with data from a genome-
wide RNA-mediated interference screen. We identify specific DNA amplifications and essential 
genes within these amplicons representing key genetic drivers, including known and new 
regulators of oncogenesis. The genes identified include eight that are essential for cell 
proliferation (FGD5, METTL6, CPT1A, DTX3, MRPS23, EIF2S2, EIF6 and SLC2A10) and are 
uniquely amplified in patients with highly proliferative luminal breast tumors, a clinical subset of 
patients for which few therapeutic options are effective. This general strategy has the potential to 
identify therapeutic targets within amplicons through an integrated use of genomic data sets.1 
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INTRODUCTION 
 Tumorigenesis is driven by a combination of inherited and acquired genetic alterations 
resulting in a complex and heterogeneous disease. The ability to dissect this heterogeneity is 
critical to understanding the relevance of these alterations for disease phenotypes but also to 
enable the development of rational therapeutic strategies that can match the characteristics of the 
individual patient's tumor. Many studies, including reports from The Cancer Genome Atlas 
(TCGA) project, have made use of the power of multiplatform genomic analyses to identify 
known and new genetic drivers of tumor phenotypes [1–3]. This has led to the identification of 
disease subgroups with distinct characteristics and, in some instances, distinct genetic 
mechanisms of disease [1, 2, 4]. The strength of this approach relies on the integration of large-
scale genomic data to reveal biological covariation that cannot be identified when using a single 
technology. A weakness of this approach is in the interpretation of the underlying biology, which 
generally represents an inference about pathway activity based on prior knowledge concerning 
an individual gene mutation or protein alteration. 
 Altered signaling pathway activity is an important determinant of the biology of a tumor 
and may predict therapeutic response; therefore, identifying the mechanisms driving key 
tumorigenic pathways is essential to understanding the transformation process [2, 5–8]. To take 
advantage of the vast amounts of existing genomic data, we used a series of experimentally 
derived gene expression signatures that are capable of measuring oncogene or tumor suppressor 
pathway activity, aspects of the tumor microenvironment and other tumor characteristics, 
including proliferation rate, as a framework by which to integrate multiple forms of genomic 
data. Our results identify patterns of oncogenic signaling within each of the molecular subtypes 
of breast cancer, many of which correlate directly with DNA copy number aberrations. By 
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further analyzing functional data from a genome-wide RNA-mediated interference (RNAi) 
screen [9], we identified genes that are essential for cell viability in a pathway-dependent and, in 
some cases, subtype-dependent manner. Our results identify a small number of DNA 
amplifications as potential drivers of proliferation in poor-outcome luminal breast cancers, and in 
general terms, we outline an approach that could be applied to many other tumor types for which 
multiplatform genomic data exist. 
 
MATERIALS AND METHODS 
 Gene expression data. Agilent custom 244K whole-genome gene expression microarray 
data for human breast cancer samples was acquired from the TCGA project [2] data portal. 
Samples were filtered to include only those 476 samples for which Affymetrix SNP 6.0 data was 
present. As previously described [2], (TCGA) data were median centered for each gene. Illumina 
HT-29 v3 expression data for the METABRIC project (n = 1,992 samples) were acquired from 
the European Genome-phenome Archive at the European Bioinformatics Institute, and data were 
median centered for each gene [3]. Expression data for a panel of 51 breast cancer cell lines were 
acquired from GEO (GSE12777) [41]. Affymetrix U133+2 data were MAS5.0 normalized using 
the Affymetrix Expression Console (ver1.2.1.20) and log2 transformed. Expression probes were 
collapsed using the median gene value with the GenePattern [56] module CollapseProbes. 
 Affymetrix SNP 6.0 data. DNA copy number values were determined in 490 TCGA 
primary breast tumors (476 of which had matched mRNA expression data) and 1,992 
METABRIC primary breast tumors using Affymetrix 6.0 SNP arrays as described previously [2, 
3]. Copy number segmentation and segment calls (i.e., NEUT, AMP, GAIN, HOMD or HETD) 
were performed using the circular binary segmentation (CBS) algorithm as described previously 
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[2, 3]. Using the hg19 build annotation from the UCSC genome browser, genes were selected if 
they fell completely within a CBS-identified copy number segment. Genes that were not found 
completely within a copy number segment across any sample were filtered out. In the 
METABRIC data set, the copy number call gene matrix was determined from genes that fell 
completely within a CBS-identified copy number segment. Out of the 12 genes of interest, 
SNX21, ZBTB46 and DNAJC5 were not found completely within a CBS-identified segment 
among the METABRIC samples and were excluded from further analyses. 
 Gene expression signatures. A panel of 52 previously published gene expression 
signatures was used to examine patterns of pathway activity and/or microenvironmental states 
(Table 3.1). To implement each signature, the methods detailed in the original studies were 
followed as closely as possible. Of these 52 signatures, 22 signatures [10, 11, 32] were originally 
developed using a Bayesian binary regression strategy and are comprised of Affymetrix probe 
sets with positive and negative regression weights. These signatures were translated to a form 
that could be applied to non-Affymetrix expression data. For each signature, we excluded those 
probe sets with a negative correlation coefficient. The remaining probe sets with a positive 
coefficient were then translated to the gene level, and replicate genes were merged. To apply a 
given signature to a new data set, the expression data were filtered to contain only those genes 
that met the previous criteria, and the mean expression value was calculated using all genes 
within a given signature that were present in more than 80% of samples. The list of genes in each 
modified signature is shown in the online version of the paper, along with the scores for the 
TCGA data and cell line data set. 
 Statistical analyses of signature scores. To quantify differences in patterns of signature 
scores across subtypes, ANOVA followed by Tukey's post-test for pairwise comparisons was 
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used (as shown in Figure 3.1b). To investigate the level of concordance between each of the 52 
signatures, the pathway scores calculated for each sample in the TCGA data set (data available 
online) were analyzed. The R values calculated by Pearson correlation are reported in Figure 3.2 
and the source data available online. 
 Identification of point mutations as a function of pathway activity. To compare the 
frequencies of mutations, the 35 genes identified as being significantly mutated in human breast 
cancer [2] were assessed in the context of the 11-gene PAM50 proliferation signature [31]. A 
Fisher's exact test (Bonferroni corrected) was used to compare the frequency of mutations in 
samples with high (top quartile) and low (all other samples) pathway activity in LumA, LumB 
and HER2E (n = 388) samples. The frequencies of mutations associated with each group for each 
signature are summarized in the online version of the paper. 
 Identification of CNAs as a function of pathway activity. To identify CNAs, two 
analysis methods were used independently. Spearman rank correlation, both positive and 
negative, was used to compare gene-level segment scores with predicted pathway activity. To 
compare the frequencies of amplifications and losses, a Fisher's exact test was used to compare 
the frequencies of either gene-specific copy number gains and amplifications or deletions (both 
LOH and deletions) against nonamplified or nondeleted samples. Samples in the top quartile of 
the calculated pathway activity were compared to those in the bottom three quartiles. For each 
analysis, the %log10 Bonferroni-adjusted P values are reported (Figure 3.3 and 3.4). To identify 
genes that were significant across both methods, a threshold of q < 0.01 (Bonferroni corrected) 
was set for validation (Figure 3.5) and q < 0.05 for discovery (Figure 3.6). The Bonferroni-
corrected P values for the positive and negative Spearman rank correlation for each gene and 
each signature are reported in the online version of the paper. The frequency of copy number 
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gains in the top quartile compared to all other samples, as well as the Bonferroni-corrected P 
values calculated by Fisher's exact test, are reported for each gene and each signature and are 
available in the online version of the paper. 
 Analysis of genome-wide RNAi proliferation data. To identify genes that are required 
for cell viability in a signature-dependent manner, data from a previously published genome-
wide RNAi screen carried out on a panel of breast cancer cell lines were analyzed [9]. The Gene 
Active Ranking Profile (GARP)-normalized data were obtained from the COLT database and 
filtered to include only those 27 cell lines for which gene expression data (GSE12777) were also 
available (acquired February 2013). To identify genes essential for pathway-dependent cell 
proliferation, a negative Spearman correlation was performed comparing predicted pathway 
activity and GARP score for each sample. A threshold of P < 0.05 was considered significant for 
all analyses. 
 Analysis of mRNA expression in copy number–neutral samples. To assess mRNA 
expression in luminal tumors lacking CNAs of each candidate gene, luminal and HER2E 
samples from the TCGA (n = 388) and METABRIC (n = 1,333) studies were grouped into those 
with high (top quartile) and low (all other samples) pathway activity. Samples with copy number 
gains (including high-level amplifications or gains) or losses (both LOH and homozygous 
deletions) were excluded, and a t test was used to examine statistical differences between the 
expression levels of genes in each cohort. 
 Survival analyses. To investigate the effect that candidate gene amplification has on 
disease-specific survival, clinical data for the 1,992 patients in the METABRIC study were 
obtained [3]. The 11-gene PAM50 proliferation signature [31] was applied to all 1,992 samples 
by calculating the median value of the signature for each sample. For survival analyses, patients 
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that died of causes unrelated to breast cancer and patients without a date of death were censored. 
We extracted patients with tumors classified as LumA, LumB or HER2E and for whom survival 
data were reported (n = 1,333). For survival analysis of the TCGA data set [2], we extracted 
patients with tumors classified as LumA, LumB or HER2E and for whom clinical data were 
available (September 2012). Disease-specific survival was calculated by comparing samples with 
amplification (including copy number gains and high-level amplification) of a candidate gene 
against those without. In each data set, patients without a CNA call for a specific gene were 
excluded from the survival analysis. For each analysis, significance was calculated by a log-rank 
test, and the hazard ratio (HR) is reported. To compare the effect of candidate gene copy number 
status on common prognostic markers, including proliferation (PAM50 proliferation signature), 
molecular subtype (PAM50), tumor stage, node status, ER status, HER2 status and age at 
diagnosis, a multivariate Cox model was used. 
 
RESULTS 
Subtype-specific patterns of oncogenic signaling 
 To objectively identify genetic drivers of breast cancer, we examined genomic-based 
patterns of oncogenic pathway activity, the tumor microenvironment and other important 
features in human breast tumors using a panel of 52 previously published gene expression 
signatures (Table 3.1 and the online version of the paper) [10 –32]. We applied each signature to 
the breast cancer gene expression microarray data (n = 476) from the TCGA project (online 
version of the paper), for which the molecular intrinsic subtype had been determined [2]. 
Consistent patterns of pathway activity emerged for each subtype (as illustrated in Figure 3.1a), 
and we quantitatively assessed these patterns using an analysis of variance (ANOVA) test 
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followed by Tukey's test for pairwise comparison (Figure 3.1b and Table 3.2). Analyzing 
differences across subtypes on the basis of these 52 features demonstrated that the strongest 
correlation between samples existed within each molecular subtype (Figure 3.7). 
 The patterns of pathway activity recapitulated known characteristics of each subtype, 
including dysregulation of pathways that can be linked to female hormone receptors, oncogenes 
and/or tumor suppressor mutation status (Figure 3.1). For example, basal-like tumors, which 
represent ~80% of triple-negative breast cancers, are characterized by low hormone receptor 
signaling, mutant p53 signaling and high expression of proliferation pathway activity (Figure 
3.1). Likewise, HER2-enriched (HER2E) tumors show high expression of the HER2 [11] and 
HER2 amplicon (HER2-AMP) [12] signatures, whereas luminal A (LumA) tumors show high 
hormone receptor signaling and wild-type p53 signaling. Highly proliferative LumB tumors, 
which also show some hormone receptor signaling, are distinguished from less proliferative 
LumA samples by increased proliferation-associated pathways. Thus, these data robustly 
recapitulate many previously published pathway and subtype associations. 
 Calculating a Pearson correlation coefficient to assess the concordance between each of 
the 52 signatures (Figure 3.2 and data available online) identified strong relationships between 
independent signatures for a given pathway, as well as between related pathways. For example, 
two MYC signatures [11, 15, 32] demonstrated an R value of 0.72, whereas PIK3CA [18] and 
PTEN-deleted [27] signatures had an R value of 0.82. Signatures scoring different pathways 
were also concordant; for instance, MYC-mediated regulation of E2F signaling [33] was 
identified by the association between the RB loss of heterozygosity (RB-LOH) [16] and MYC 
[15] signatures (R = 0.79), whereas EGFR-mediated activation of STAT33 signaling [34] was 
recapitulated by the EGFR [11, 32] and STAT3 [11, 32] (R = 0.72) signatures. These results 
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provide a measure of validity for each signature, but because differences do exist between 
signatures for a specific pathway, the results suggest that each signature provides an opportunity 
to investigate a particular pathway, taking into account the genetic manipulation used to develop 
a given signature. 
 
Characterization of pathway-specific copy number alterations 
 We next used DNA copy number data from the TCGA project (n = 476) to identify copy 
number alterations (CNAs) associated with pathway activity (Figure 3.5a). We first identified 
genes for which CNAs were positively (or inversely) correlated with pathway activity using a 
Spearman rank correlation (Bonferroni corrected to control the familywise error rate) to assess 
the relationship between pathway score and gene-level DNA segment score (Figure 3.3 and data 
available online). Second, we used a Fisher's exact test (Bonferroni corrected) to calculate the 
frequency of CNA gains (including high-level amplifications and gains) or losses (including 
LOH and deletions) in samples with high (top quartile) pathway activity compared to all other 
samples (low activity) (Figure 3.4 and data available online). To reduce potential false-positive 
results associated with either strategy alone, for each signature we focused on those genes that 
were significant in both analyses (Figure 3.5a); potential drivers of pathway activity had a 
positive correlation and a higher amplification frequency in samples with high pathway activity, 
whereas potential repressors had a negative correlation and increased frequency of copy number 
losses. Mapping genes that met these criteria to chromosomal loci identified pathway-specific 
patterns of CNAs (Figure 3.5b). Consistent with previous studies reporting that basal-like tumors 
have a higher incidence and larger spectrum of CNAs [2, 35], pathways associated with basal-
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like tumors had more complex patterns of CNAs when compared to luminal-associated 
pathways. 
 To further assess the validity of this strategy, we investigated the relationship between 
pathway activity and a chromosomal alteration of known causative activity. We first focused on 
the HER2-AMP signature [12], as this signature is comprised of genes located at the 17q loci and 
the ERBB2/17q amplification is the dominant driver of this pathway. ERBB2 was amplified in 
84.9% of samples with high (top quartile) pathway activity compared to in 7.3% of low-scoring 
samples (q = 1.1 & 10%55); likewise, this relationship had a positive Spearman rank correlation (q 
= 2.4 & 10%108) (Figure 3.5c and data available online). Although several other alterations, 
including MYC amplification (q = 1.1 & 10%2 and q = 6.3 & 10%3), were also associated with this 
signature, thus identifying a previously known relationship [36], ERBB2/17q amplification was 
the dominant alteration identified, providing a robust positive control for this strategy. As 
expected, we observed similar results when analyzing the HER2 pathway using the 
independently developed HER2 [11, 32] signature (data available online). 
 We further validated this strategy by assessing the relationship between CNAs and 
pathways that are associated with a more complex genomic landscape. Previous studies from our 
group have suggested that the HER1-C2 [13] signature measures predominantly the RAS-RAF-
MEK arm of the EGFR pathway [13]. Consistent with this observation, we detected a correlation 
between the HER1-C2 signature (q < 0.01) and GRB2, SOS1, KRAS, BRAF, PIK3CA, PIK3CB 
and MYC genomic DNA amplifications, as well as a negative correlation (q < 0.01) with loss of 
NF1 and the PI3K repressors INPP4B and PTEN (Figure 3.5d and data available online). We 
then analyzed CNAs associated with the RB-LOH [16] signature (Figure 3.5e and data available 
online) and identified associations between it and CNAs of known RB-E2F components, 
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including loss of RB1 and gains of E2F1 and/or E2F3. Consistent with the role of the RB-E2F 
pathway in mediating cell cycle progression and proliferation [37], CCND2, CCND3 and MYC 
amplification also correlated with this signature. Collectively these results demonstrate that this 
strategy is able to link CNAs with pathway activity and does so by focusing on all aspects of the 
pathway, often beyond the dominant regulator, potentially allowing for the identification of new 
regulatory components. 
 
Identification of amplified genes linked to pathway activity 
 Given the ability of this strategy to identify known CNAs of pathway activity, we next 
used this approach to identify new drivers of pathway activity. Because highly proliferative 
luminal tumors have a poor prognosis and poor responses to existing therapies [38, 39], we 
sought to identify amplified genes and/or CNAs associated with our previously published 11-
gene PAM50 proliferation signature with the hope that these might represent targetable drivers 
of oncogenesis. 
 To identify those genes that are altered specifically in highly proliferative luminal tumors 
while excluding those that are associated with proliferation irrespective of subtype, we 
performed analyses on two subsets of samples: all tumors and all non–basal like tumors 
(henceforth called luminal tumors). Some rationale for this binary distinction comes from recent 
TCGA studies in which 12 tumor types were studied simultaneously, and the results showed that 
breast tumors formed two groups, namely basal-like and all other breast tumors (called luminal 
and including HER2+ tumors), suggesting that breast cancer might be considered broadly as two 
main disease types [40]. 
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 Examining the TCGA breast cancer data set using the PAM50 proliferation signature 
[31], we found that basal-like, LumB and HER2E tumors had the highest proliferation levels 
(Figures 3.8a, b), with the top quartile (Figure 3.8c) comprised of patients with basal-like 
(49.6%), LumB (33.6%) and HER2E (16.8%) tumors, whereas the top quartile of proliferative 
luminal tumors (Figure 3.8d) contained patients with LumB (68.0%) and HER2E (32.0%) 
tumors. Using the PAM50 proliferation signature, we examined the frequency of CNA gains and 
losses in highly proliferative (top quartile) tumors relative to less proliferative samples 
irrespective of subtype using the statistical strategies discussed previously (Figures 3.8e, f and 
data available online). To identify genes that are specifically amplified in highly proliferative 
luminal breast cancer, we repeated these analyses using the luminal tumor subset (Figures 3.8g, h 
and data available online). Analyzing both populations of tumors identified three classes of 
proliferation-associated regions (q < 0.05): (i) CNAs associated irrespective of subtype, (ii) 
CNAs altered in basal-like tumors, and (iii) CNAs altered in highly proliferative luminal tumors. 
These results allowed us to focus our analyses on those genes within regions that are uniquely 
altered in highly proliferative luminal tumors by censoring proliferation-associated genes that are 
altered in basal-like breast cancer (e.g., TP53 or INPP4B loss) or that are altered irrespective of 
molecular subtype (e.g., RB1 loss or MYC amplification). These analyses identified a number of 
regions, including 3p25, 5p15, 11q13, 17q22 and 20q11-13, that were uniquely amplified in 
highly proliferative luminal tumors. 
 
Identification of pathway-specific essential genes 
 To distinguish essential from nonessential genes in amplified regions that are associated 
with proliferation in luminal tumors, we next examined data from a genome-wide RNAi screen 
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of multiple breast tumor–derived cell lines [9]. We applied the 52 gene expression signatures to a 
panel (GSE12777) [41] of breast cancer cell lines (Figure 3.9 and data available online), 27 of 
which had mRNA expression data and were also part of an RNAi proliferation screen in which a 
genome-wide shRNA library (~16,000 genes) had been used to identify essential genes (Figure 
3.10a) [9]. For each signature, we used a negative Spearman rank correlation to identify 
pathway-specific essential genes (Figure 3.10b and data available online) by comparing the 
pathway score against the normalized shRNA score across the panel of 27 cell lines. These 
analyses identified inverse relationships between the abundance of shRNAs targeting key 
regulatory genes and pathway scores. For instance, examining the ER [11, 32], HER2 [11, 32] or 
STAT1 [42] signatures as controls (Figures 3.10c–e) showed a negative correlation between 
pathway score and shRNA against ESR1 (P = 0.0143), ERBB2 (P = 0.0227) and STAT1 (P = 
0.0049) or JAK3 (P = 0.00013), respectively. These associations were expected for the ER and 
HER2 pathways given the relationship between HER2 or ER-# mRNA and/or protein expression 
and the response of cell lines or tumors to trastuzumab or anti-estrogen therapies, respectively. 
These results confirm that this approach is able to identify essential genes that are known to be 
functionally associated with pathway activity, thereby suggesting that these data can serve as a 
biological filter to distinguish pathway-specific essential from nonessential genes. 
 
Amplified essential genes linked to luminal tumor proliferation 
 We next sought to distinguish between essential and nonessential genes within regions 
amplified specifically in highly proliferative luminal tumors. For each subset of tumors, we 
identified genes in amplified regions that were positively correlated with proliferation and 
showed an increased amplification frequency (q < 0.05). We next examined the RNAi data in all 
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breast cancer cell lines (Figure 3.11a) and in luminal HER2+ cell lines (Figure 3.11b) in the 
context of the PAM50 proliferation signature (data available online). Comparing the results of 
these four analyses (Figure 3.6a) identified 19 genes that were uniquely essential for cell 
viability in luminal cell lines and that were amplified in highly proliferative luminal tumors 
(Figure 3.6b). Two additional genes, DNAJC5 and SNX21, were identified by RNAi analysis but 
were initially overlooked in the CNA analyses, as they were located at the cusp of two 
segmented regions; however, because genes overlapping both 5' and 3' of these genes were 
amplified, we included them in further investigations. Of these 21 candidate genes, 12 showed a 
significant relationship (P < 0.05) between DNA copy number levels and mRNA expression in 
luminal tumors (Figure 3.12). Notably, half of these genes were located at 20q11-13 (EIF2S2, 
EIF6, SLC2A10, SNX21, ZBTB46 and DNAJC5), with two located at 3p25.1 (FGD5 and 
METTL6) and the remaining genes located at 5p15 (TRIO), 11q13 (CPT1A), 12q13 (DTX3) and 
17q22-23 (MRPS23). In contrast, permuting the data labels 1,000 times for each analysis, in all 
samples and in luminal samples alone, identified no gene that met this statistical threshold, 
suggesting that the 21 candidate genes could not have been identified by chance alone. 
 
Validation of identified candidate genes 
 We next confirmed that the majority of the identified genes were significantly amplified 
in highly proliferative luminal breast tumors by analyzing an independent breast tumor data set 
(Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), n = 1,992) for 
which both mRNA expression and genomic DNA CNA data were available [3]. Of the 12 genes 
identified, 9 (FGD5, METTL6, TRIO, CPT1A, DTX3, MRPS23, EIFS2S, EIF6 and SLC2A10) 
were present on both platforms used in the METABRIC study. Each of these genes (Figure 3.13) 
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showed a significant (P < 0.05) relationship between CNA status and mRNA expression in 
luminal breast tumors (n = 1,333). Notably, eight of the nine genes, the exception being TRIO, 
also showed an increased amplification frequency (P < 0.05) in highly proliferative (top quartile) 
luminal tumors (Figure 3.14), thus recapitulating one of our main findings. 
 To confirm that DNA mutations of genes associated with proliferation in luminal tumors 
did not confound these results, we examined the relationship between the 11-gene proliferation 
score and the mutation frequency of the 35 previously identified significantly mutated genes in 
human breast cancers reported by TCGA [2]. Using a Fisher's exact test (Bonferroni corrected), 
we determined that only TP53 (q = 7.0 & 10%10) and MAP3K1 (q = 5.0 & 10%3) mutations 
occurred at significantly different frequencies in highly proliferative (top quartile) luminal 
tumors compared to all other samples; TP53 mutations occurred more frequently (51.6% 
compared to 18.6%) and MAP3K1 (2.1% compared to 12.4%) mutations occurred less frequently 
in highly proliferative luminal tumors (Table 3.3). Moreover, we found no significant 
relationship between MAP3K1 or TP53 mutation status (Bonferroni-corrected Fisher's exact test, 
q > 0.05) and the amplification status of each candidate gene (Table 3.4) in highly proliferative 
luminal tumors. 
 We then investigated whether expression of the candidate genes, independent of CNA 
status, was associated with proliferation in luminal breast tumors. By comparing the mRNA 
expression patterns of each candidate gene in highly proliferative luminal tumor samples (top 
quartile) against all other samples, we found that tumors lacking CNAs of each candidate gene 
fell into three categories: those that exhibited a positive relationship between mRNA expression 
and the PAM50 proliferation signature (EIF2S2, EIF6, CPT1A and MRPS23), those that were 
anticorrelated with the signature (DTX3) and those that showed no correlation (FGD5, METTL6 
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and SLC2A10) between data sets (Figure 3.15). These data suggest that amplification is a key 
mechanism driving the expression of these genes. However, our data also suggest, not 
surprisingly, that overall high expression may be the driver for some genes, which can be 
accomplished by amplification or through other unknown means. 
 
Candidate gene amplification correlates with poor prognosis 
 Previous studies have shown that highly proliferative luminal tumors have a poor 
prognosis [38, 39]; therefore, we investigated what impact amplification of each candidate gene 
had on overall survival. From the TCGA (n = 388) [2] and METABRIC (n = 1,333) [3] data sets, 
we extracted the subset of patients with LumA, LumB or HER2E tumors for which survival data 
were available online. We first analyzed data from the TCGA project (Figures 3.16a–e), and 
despite the relatively short follow-up time (median, 1.7 years), we determined that amplification 
of FGD5 (P < 0.0001; hazard ratio (HR), 8.0), METTL6 (P = 0.0003; HR, 5.9), DTX3 (P = 
0.0387; HR, 2.6) and MRPS23 (P = 0.0078; HR, 2.9) predicted a significantly worse outcome in 
patients with luminal breast cancer, whereas CPT1A amplification had no effect on patient 
survival (P = 0.3738). Extending these analyses to the METABRIC data set (Figures 3.16f–j), 
which had a longer median survival time (7.2 years), confirmed that FGD5 (P = 0.0170; HR, 
2.0), METTL6 (P = 0.0081; HR, 2.1), DTX3 (P = 0.0098; HR, 1.8) and MRPS23 (P = 0.0020; 
HR, 1.5) amplification correlated with a poor prognosis, whereas gain of CPT1A had no effect (P 
= 0.099) on the survival of patients with luminal breast cancer. The remaining three genes 
showed no consistent effect on prognosis (Figure 3.17). Although it is possibly that other genes 
within these chromosomal loci are also prognostic, these amplified genes were associated with 
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proliferation in vivo, were prognostic in multiple patient cohorts and are essential for cell 
viability in vitro. 
 We likewise determined that for most of the identified candidate genes that failed to meet 
all our predetermined criteria, amplification alone, without a coordinate increase in mRNA 
expression, was not sufficient to affect prognosis, as only one (TMEM117) of these genes 
showed a consistently poor prognosis in the TCGA and METABRIC data sets (Table 3.5). We 
then investigated whether the 12 initial candidate genes were predictive of poor prognosis when 
compared with standard prognostic markers, including molecular subtype, tumor stage, node 
status, ER status, HER2 status, age at diagnosis and the 11-gene proliferation score, when tested 
using a multivariate analysis (Cox model). We determined that amplification of a single 
candidate gene did not consistently outperform or improve the prognostic capacity of these 
clinical and genomic variables (Appendix 4). However, these candidate genes were not identified 
to be prognostic markers, especially given that they correlate with proliferation, but instead were 
selected as likely drivers of proliferation, a highly important prognostic feature. 
 
DISCUSSION 
 Numerous studies, including many that have focused on human breast cancer, used large-
scale analyses to investigate the genomic landscape of human cancers in order to identify 
molecular heterogeneity and define new tumor subtypes not previously recognized [2, 3, 6, 11]. 
The challenge presented by these studies, and by the enormous amount of genomic data available 
from resources such as the TCGA and METABRIC projects, is how to integrate multiple forms 
of genomic data to investigate the biology of disease and how to interpret the relevance of 
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identified genomic alterations without relying on inferences of 'known' biology to determine the 
role that these alterations have in tumorigenesis. 
 In this study we utilized gene expression signatures of signaling pathways to identify 
patterns that can distinguish the known subtypes of breast cancer. These signatures were 
developed largely from controlled manipulations of the relevant pathways in vitro and are thus 
based on experimental evidence for pathway activation as opposed to extrapolations of pathway 
activity achieved from analyses of annotated gene lists. Therefore, the use of an experimentally 
derived pathway signature, as opposed to an analysis of a single genomic alteration, provides a 
measure of pathway activity irrespective of how the pathway may have been activated. For 
instance, a given pathway can be active in a subset of tumors as a result of either an activating 
alteration (i.e., E2F1 or E2F3 amplification) or an independent event that inactivates a negative 
regulator of the pathway (i.e., RB1 loss and/or mutation), which nevertheless achieves the same 
end result (i.e., DNA replication and cell proliferation); notably, we identified these four genetic 
events as being statistically associated with the RB-LOH signature [16], which is dominated by 
E2F-regulated genes and is a strong indicator of cell proliferation and prognosis. 
 Proliferation is one of the most powerful prognostic features in breast cancers, especially 
for ER+ cancers [38, 39]. Because proliferation is so important, we used a gene expression 
signature of proliferation as a means to integrate the DNA copy number data, along with data 
from a genome-wide RNAi screen of luminal breast cancer cell lines, to identify luminal-specific 
genetic drivers of proliferation. We identified 12 genes that were amplified uniquely in highly 
proliferative luminal tumors in the TCGA data set, have a correlation between mRNA expression 
and DNA copy number and have been shown to be essential for luminal breast cancer cell line 
viability; we validated 8 of these genes using the independent METABRIC data set. Whereas 
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FGD5, METTL6, DTX3 and MRPS23 amplification was prognostic in luminal tumors, these and 
many of the other identified genes have been reported previously to regulate tumorigenic 
characteristics, albeit not necessarily in human breast cancer. For example, FGD5 has been 
shown to regulate the proangiogenic function of VEGF [43], potentially leading to increased 
proliferation. DTX3 purportedly promotes Notch signaling [44, 45], whereas EIF6 is a Notch-
dependent regulator of cell invasion and migration [46], and its inhibition restricts 
lymphomagenesis and tumor progression [47]. MRPS23 expression is associated with 
proliferation, oxidative phosphorylation, invasiveness and tumor size in uterine cervical cancer 
[48]. METTL6 has been reported to contribute to cytotoxic chemotherapy sensitivity in lung 
cancers [49]. 
 Several previous studies have identified chromosomal regions altered specifically in 
subsets of breast cancer, including 3p25 (encompassing METTL6 and FGD5) [2] and 11q13 
(CPT1A) [3] in luminal breast tumors; however, these studies neither discriminated between 
essential and nonessential genes within a specific amplicon nor identified the functional 
consequences of these alterations. In contrast, we have shown that these regions are amplified 
uniquely in highly proliferative luminal tumors, and we distinguish between amplified genes that 
are essential for cell proliferation and are thus likely contribute to tumorigenesis and those that 
are amplified but are not essential. For instance SRC (20q12-13), which is co-amplified with 
EIF6, is similarly amplified in a significant (q < 0.01) percentage of highly proliferative luminal 
tumors (data available online) but was not identified as being essential in highly proliferative 
luminal breast cancer cell lines in the RNAi screen (data available online). Notably, in addition 
to its role in regulating translation [50] and Notch signaling [46], EIF6 has been reported to link 
integrin-"4 to the intermediate filament cytoskeleton [51], potentially leading to downstream 
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activation of SRC signaling. These results may explain some of the paradoxical findings of SRC 
in that it may contribute to proliferation status but may not be essential, whereas a gene very near 
it, which is also linked to proliferation, is essential for cell viability in vitro. Clearly, additional 
experiments are needed to address this issue, but these results highlight the complex nature and 
importance of this specific amplicon. 
 A major challenge to translating these findings into the clinic is the identification of 
genes within amplicons that are therapeutically targetable. One such event may be amplification 
of 11q13-14 (CPT1A), which was recently reported [3] to be a defining feature of a high-risk 
ER+ subgroup (integrative cluster 2) and correlates with a poor prognosis in esophageal 
squamous cell carcinoma [52]. We identified CPT1A as the only gene within the amplified 
11q13 locus that is required for cell viability within the confines of the proliferation signature 
and luminal cell lines, suggesting that repression of CPT1A could affect the proliferative 
phenotype of these tumors. Consistent with this hypothesis, it was recently reported that RNAi-
mediated downregulation, or drug-mediated inhibition, of CPT1A inhibited cancer cell line 
proliferation, migration and metastasis [53-55], although not in breast cancer cell lines. In 
addition, a specific inhibitor of CPT1A (ST-1326) repressed tumor formation and proliferation in 
an Eµ-Myc mouse model of Burkett's lymphoma [55]. 
 Collectively these data demonstrate the ability of this cross-platform genomics approach 
to identify new oncogenes that are essential for cell viability and are amplified in a subset of 
patients with highly proliferative luminal breast cancer. These data suggest that not only are 
these identified genes potential drivers of oncogenesis and that an emphasis should be placed on  
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elucidating their role in breast tumorigenesis but also that they, or their associated pathways, may 
serve as new therapeutic targets in a subset of human breast cancers for which limited 
therapeutic opportunities currently exist.  
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Table 3.1 Summary of Gene Expression Signatures 
 
Signature Pathway References 
ACIDOSIS Acidosis response PMID: 21672245, PMID: 22078435 
ACTIVE 
ENDOTHELIUM Activated endothelium PMID: 23975155 
AKT Akt signaling PMID: 20335537, PMID: 22078435 
"CATENIN Beta catenin activation PMID: 20335537, PMID: 22078435 
BMYB BMYB signaling PMID: 19043454 
BRCA1 BRCA1 signaling PMID:11823860 
CMYB CMYB signaling PMID:20949095 
E2 ACTIVATED (IE) Estrogen activated signaling PMID:16505416 
E2 REPRESSED (IIE) Estrogene repressed signaling PMID:16505416 
E2F1 E2F1 signaling PMID: 20335537, PMID: 22078435 
EGFR EGFR activation PMID: 20335537, PMID: 22078435 
ER Estrogen receptor signaling PMID: 20335537, PMID: 22078435 
ESC HUMAN Human Embryonic Stem Cell PMID:18397753 
FOS JUN Fos-Jun kinase signaling PMID: 21214954 
GATA3 Wild-type GATA3-mediated signaling PMID:15361840 
GLUCOSE DEPLETION Glucose depletion response PMID: 21672245, PMID: 22078435 
GYCOLYSIS Glycolysis response PMID:19291283 
HER1 C1 HER1/EGFR Cluster 1 PMID:17663798 
HER1 C2 HER1/EGFR Cluster 2 PMID:17663798 
HER1 C3 HER1/EGFR Cluster 3 PMID:17663798 
HER2 HER2/ERBB2 overexpression PMID: 20335537, PMID: 22078435 
HER2 AMP HER2/ERBB2 amplification PMID: 21214954 
HYPOXIA Hypoxia response PMID: 21672245, PMID: 22078435 
IFNA Interferon alpha response PMID: 20335537, PMID: 22078435 
IFNG Interferon gamma response PMID: 20335537, PMID: 22078435 
LACTIC ACID Lactic acidosis response PMID: 21672245, PMID: 22078435 
LKB1 LKB1 signaling PMID:17676035 
MYC DUKE Myc activation PMID: 20335537, PMID: 22078435 
MYC UNC Myc signaling PMID:19690609 
P53 p53 signaling PMID: 20335537, PMID: 22078435 
P53 MUT Mutant p53 signaling PMID:17150101 
P53 WT Wild-type p53 signaling PMID:17150101 
P63 p63 activation PMID: 20335537, PMID: 22078435 
PI3K PI3 kinase signaling PMID: 20335537, PMID: 22078435 
PIK3CA PI3 kinase signaling PMID:22552288 
PR Progesterone Receptor PMID: 20335537, PMID: 22078435 
PROLIFERATION Proliferation PMID: 21214954 
PROLIFERATION 
(PAM50) Proliferation PMID:19204204 
PTEN WT Wild-type PTEN signaling PMID: 17452630 
PTEN DEL Mutant PTEN signaling PMID: 17452630 
RAS Ras activation PMID: 20335537, PMID: 22078435 
RB LOH Loss of RB expression PMID:18782450 
SRC Src kinase PMID: 20335537, PMID: 22078435 
STAT1 Stat1 activation PMID: 19272155 
STAT3 Stat3 activation PMID: 20335537, PMID: 22078435 
STEM CELL Stem cell associated expression PMID:15931389 
STROMAL DOWN Low stromal cellularity PMID:19648928 
STROMAL UP High stromal cellularity PMID:19648928 
TGFB Tumor growth factor beta PMID: 20335537, PMID: 22078435 
TNFA Tumor necrosis factor alpha PMID: 20335537, PMID: 22078435 
VEGF/HYPOXIA Vascular endothelial growth factor / hypoxia signaling PMID:19291283 
WOUND RESPONSE Wound response in breast cancer microenvironment PMID:19887484 
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Table 3.2 Summary of ANOVATukey test analysis of subtype pathway score  
 
Pathway ANOVA 
Basal-
HER2 
Basal-
LumA 
Basal-
LumB 
HER2-
LumA 
HER2-
LumB 
LumA-
LumB 
BRCA1 <0.0001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
HER1 C2 <0.0001 <0.001 <0.001 <0.001 <0.001 <0.05 <0.001 
P53 Mut <0.0001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
E2 Repressed (IIE) <0.0001 >0.05 <0.001 <0.001 <0.001 >0.05 <0.001 
Proliferation (PAM50) <0.0001 <0.01 <0.001 <0.001 <0.001 >0.05 <0.001 
ESC Human <0.0001 <0.01 <0.001 <0.001 <0.001 >0.05 <0.001 
B-catenin <0.0001 <0.001 <0.001 <0.001 <0.001 >0.05 <0.001 
BMYB <0.0001 <0.001 <0.001 <0.001 <0.001 >0.05 <0.001 
PROLIFERATION <0.0001 <0.001 <0.001 <0.001 <0.001 >0.05 <0.001 
PTEN DEL <0.0001 <0.001 <0.001 <0.001 <0.001 >0.05 <0.001 
RB LOH <0.0001 <0.001 <0.001 <0.001 <0.001 >0.05 <0.001 
HER1 C3 <0.0001 <0.001 <0.001 <0.001 <0.001 >0.05 <0.001 
MYC (DUKE) <0.0001 <0.001 <0.001 <0.001 <0.001 >0.05 <0.001 
Activated Endothelium <0.0001 <0.001 <0.001 <0.001 <0.001 >0.05 <0.001 
MYC (UNC) <0.0001 <0.001 <0.001 <0.001 <0.001 <0.05 <0.001 
PIK3CA <0.0001 <0.001 <0.001 <0.001 <0.001 >0.05 <0.001 
RAS <0.0001 <0.001 <0.001 <0.001 <0.001 >0.05 <0.001 
HER1 C1 <0.0001 <0.01 <0.001 <0.001 <0.001 <0.001 <0.001 
GLYCOLYSIS <0.0001 >0.05 <0.001 <0.001 <0.001 <0.001 <0.001 
VEGF/Hypoxia <0.0001 <0.001 <0.001 <0.001 <0.001 >0.05 >0.05 
E2F1 <0.0001 >0.05 <0.001 <0.05 <0.001 >0.05 <0.001 
PI3k <0.0001 <0.001 <0.001 <0.001 <0.001 >0.05 <0.001 
Stem Cell <0.0001 <0.01 <0.001 <0.05 <0.001 >0.05 <0.001 
P63 <0.0001 <0.001 <0.01 <0.001 <0.001 >0.05 <0.001 
IFNA 0.0008 >0.05 <0.01 >0.05 <0.05 >0.05 <0.05 
IFNG 0.0005 >0.05 <0.001 >0.05 >0.05 >0.05 >0.05 
STAT1 <0.0001 >0.05 <0.001 <0.01 <0.001 >0.05 <0.01 
TNFA <0.0001 <0.05 <0.001 <0.001 <0.01 <0.001 >0.05 
Glucose Depeletion <0.0001 <0.05 <0.001 <0.001 <0.001 <0.001 >0.05 
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Table 3.2 Summary of ANOVATukey test analysis of subtype pathway score (Continued) 
 
Pathway ANOVA 
Basal-
HER2 
Basal-
LumA 
Basal-
LumB 
HER2-
LumA 
HER2-
LumB 
LumA-
LumB 
CMYB 0.0957 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 
HYPOXIA <0.0001 >0.05 <0.01 <0.001 <0.05 <0.001 >0.05 
AKT 0.0004 >0.05 <0.001 <0.05 >0.05 >0.05 >0.05 
FOS JUN <0.0001 >0.05 <0.001 >0.05 <0.001 >0.05 <0.001 
ACID <0.0001 <0.01 >0.05 <0.001 <0.001 >0.05 <0.001 
Stromal UP <0.0001 >0.05 <0.001 >0.05 <0.01 >0.05 <0.001 
Wound Response <0.0001 >0.05 >0.05 <0.001 <0.01 <0.05 <0.001 
LKB1 <0.0001 >0.05 >0.05 <0.001 >0.05 <0.001 <0.001 
HER2 <0.0001 <0.001 >0.05 <0.001 <0.001 <0.001 <0.001 
EGFR <0.0001 >0.05 >0.05 <0.001 >0.05 <0.001 <0.001 
STAT3 <0.0001 >0.05 <0.001 <0.001 >0.05 <0.001 <0.001 
TGFB <0.0001 >0.05 >0.05 <0.001 >0.05 <0.001 <0.001 
GATA3 <0.0001 <0.001 >0.05 <0.001 <0.01 <0.001 <0.001 
HER2AMP <0.0001 <0.001 >0.05 >0.05 <0.01 <0.001 <0.05 
Lactic Acidosis <0.0001 <0.001 <0.001 <0.001 >0.05 >0.05 >0.05 
Stromal DOWN <0.0001 >0.05 <0.001 <0.001 >0.05 >0.05 >0.05 
ER <0.0001 <0.001 <0.001 <0.01 <0.001 <0.001 >0.05 
PR <0.0001 <0.001 <0.001 <0.001 <0.001 <0.001 >0.05 
P53 <0.0001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
E2 Activated (IE) <0.0001 >0.05 <0.001 <0.001 <0.001 <0.001 <0.001 
P53 WT <0.0001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
PTEN WT <0.0001 <0.001 <0.001 <0.001 <0.001 >0.05 <0.001 
SRC 0.0016 >0.05 >0.05 >0.05 >0.05 >0.05 <0.001 
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Table 3.3 Summary of SMG mutation frequency associated with Proliferation (PAM50) in 
luminal/HER2E samples  
 
GENE 
%PROLIFERATION 
(PAM50) LOW 
%PROLIFERATION 
(PAM50) HIGH 
PROLIFERATION 
(PAM50) Q 
MUT.7157_TP53 18.56 51.55 7.00E-10 
MUT.5290_PIK3CA 44.67 34.02 7.17E-02 
MUT.2625_GATA3 12.71 12.37 7.73E-01 
MUT.4214_MAP3K1 12.37 2.06 4.98E-03 
MUT.58508_MLL3 7.90 5.15 9.76E-01 
MUT.999_CDH1 9.28 5.15 3.85E-01 
MUT.6416_MAP2K4 6.53 1.03 1.14E-01 
Mut.861_RUNX1 4.47 2.06 6.58E-01 
MUT.5728_PTEN 4.12 3.09 9.70E-01 
MUT.6926_TBX3 1.72 5.15 9.39E-01 
MUT.5295_PIK3R1 2.06 6.19 4.55E-01 
Mut.207_AKT1 3.44 2.06 9.89E-01 
Mut.865_CBFB 2.06 2.06 9.10E-01 
MUT.79718_TBL1XR1 2.06 2.06 1.00E+00 
MUT.9611_NCOR1 3.78 3.09 9.66E-01 
MUT.10664_CTCF 3.44 1.03 4.05E-01 
Mut.677_ZFP36L1 1.37 1.03 1.00E+00 
MUT.2874_GPS2 1.72 0.00 6.35E-01 
MUT.23451_SF3B1 2.41 1.03 9.84E-01 
MUT.1027_CDKN1B 1.03 2.06 7.24E-01 
MUT.7399_USH2A 3.09 5.15 4.23E-01 
MUT.6103_RPGR 1.03 0.00 1.00E+00 
MUT.5925_RB1 0.34 3.09 1.15E-01 
MUT.2334_AFF2 1.72 4.12 1.00E+00 
MUT.4763_NF1 3.09 2.06 1.00E+00 
MUT.26191_PTPN22 1.03 4.12 2.39E-01 
MUT.6262_RYR2 4.12 8.25 8.61E-01 
MUT.5789_PTPRD 2.06 4.12 8.99E-01 
MUT.8590_OR6A2 1.37 0.00 1.00E+00 
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Table 3.3 Summary of SMG mutation frequency associated with Proliferation (PAM50) in 
luminal/HER2E samples (Continued) 
 
GENE 
%PROLIFERATION 
(PAM50) LOW 
%PROLIFERATION 
(PAM50) HIGH 
PROLIFERATION 
(PAM50) Q 
MUT.8347_HIST1H2BC 0.69 1.03 1.00E+00 
MUT.2854_GPR32 1.03 1.03 1.00E+00 
MUT.100310847_CLEC19A 0.00 1.03 1.00E+00 
Mut.896_CCND3 0.69 1.03 1.00E+00 
MUT.641977_SEPT13 0.69 1.03 1.00E+00 
MUT.138009_DCAF4L2 1.37 1.03 1.00E+00 
 
 
 
 
 
 
 
 
Table 3.4 Summary of the association between TP53 and MAP3K1 mutations and gene 
amplification status in highly proliferative luminal breast tumors  
 
Gene 
% 
AMP 
TP53 
WT 
% 
AMP 
TP53  
MUT 
FISHER 
Q  Gene 
% AMP 
MAP3K1 
WT 
% AMP 
MAP3K1 
MUT 
FISHER 
Q 
aCGH.152273_FGD5 23.40 22.00 0.988  aCGH.152273_FGD5 23.16 0.00 1.000 
aCGH.131965_METTL6 23.40 20.00 0.988  aCGH.131965_METTL6 22.11 0.00 1.000 
aCGH.196403_DTX3 23.40 30.00 0.988  aCGH.196403_DTX3 26.32 50.00 1.000 
aCGH.51649_MRPS23 55.32 54.00 0.988  aCGH.51649_MRPS23 55.79 0.00 1.000 
aCGH.1374_CPT1A 31.91 48.00 0.902  aCGH.1374_CPT1A 40.00 50.00 1.000 
aCGH.3692_EIF6 36.17 60.00 0.711  aCGH.3692_EIF6 49.47 0.00 1.000 
aCGH.8894_EIF2S2 34.04 52.00 0.828  aCGH.8894_EIF2S2 44.21 0.00 1.000 
aCGH.81031_SLC2A10 34.04 70.00 0.465  aCGH.81031_SLC2A10 53.68 0.00 1.000 
*** only 2 samples in this cohort have a MAP3K1 mutation*** 
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Table 3.5 Summary of overall survival associated with candidate gene amplification  
 
Gene Name 
mRNA/DNA 
Correlation 
(TCGA 
dataset) 
mRNA/DNA 
Correlation 
and 
Increased 
Amplification 
frequency 
(METABRIC) 
P-
value 
(log 
rank) 
TCGA 
Hazard 
Ratio 
(TCGA) 
P-value 
(log 
rank) 
METAB
RIC 
Hazard 
Ratio 
(METABRIC) 
AMP Gene 
Prognosis Luminal 
Breast Tumors 
FGD5 YES YES <0.0001 8 0.017 2 
Significant in both 
datasets 
METTL6 YES YES 0.0003 5.9 0.0081 2.1 Significant in both datasets 
DTX3 YES YES 0.0387 2.6 0.0098 1.8 Significant in both datasets 
MRPS23 YES YES 0.0078 2.9 0.002 1.5 Significant in both datasets 
CPT1A YES YES 0.3738 1.4 0.0991 1.2 Not significant  
EIF2S2 YES YES 0.7651 1.1 0.0053 1.5 Significant in METABRIC 
EIF6 YES YES 0.6286 1.2 0.0001 1.8 Significant in METABRIC 
SLC2A10 YES YES 0.9482 1 0.0103 1.4 Significant in METABRIC 
TRIO YES NO 0.0436 2.4 0.0594 1.4 Significant in TCGA 
SNX21 YES N/T# 0.1009 1.1 N/A N/A Not significant 
DNAJC5 YES N/T# 0.4064 1.3 N/A N/A Not significant 
ZBTB46 YES N/T# 0.6409 1.2 N/A N/A Not significant 
CD200R1 NO N/A 0.0129 3.3 0.8645 1 Significant in TCGA 
PRDM9 NO N/A 0.2114 1.7 0.0477 1.4 Significant in METABRIC 
FGF3 NO N/A 0.2899 1.4 0.0006 1.5 Significant in METABRIC 
FGF19 NO N/A 0.6053 1.3 0.0029 1.4 Significant in METABRIC 
TMEM117 NO N/A 0.0415 2.9 0.0022 2.6 Significant in both datasets 
SEMA5A NO N/A 0.082 2.2 0.2211 1.2 Not significant  
PMEPA1 NO N/A 0.5068 1.2 0.0011 1.5 Significant in METABRIC 
ANKRD56 N/T† N/A 0.1827 2.3 0.1259 1.5 Not significant  
TMEM189 N/T† N/A 0.8868 1 0.0076 1.4 Significant in METABRIC 
Twenty-one candidate genes  were identified by the integrative analysis to have an increased amplification frequency in 
highly proliferative luminal tumors and were essential in the RNAi screen.  
Of these 12 had a positive correlation between mRNA expression and DNA copy number status;  
8 were found to have the same characteristics in the METABRIC dataset.   
Genes that did not meet each criteria in the TCGA discovery dataset 
were filtered out prior to testing in the METABRIC validation dataset.    
        
BOLD: Candidate gene (n=8)       
RED: Significant in both 
datasets       
BLUE: Not significant       
Black: Significant in one dataset       
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FIGURES 
 
 
Figure 3.1 Patterns of genomic signature pathway activity in breast cancer. (a) Patterns of 
pathway activity (n = 52) were determined for each sample in the published TCGA breast cancer 
cohort (n = 476). Expression signature scores (y axis) are median centered and clustered by 
complete linkage hierarchical clustering. (b) ANOVA (P < 0.0001) for all signatures according 
to PAM50 subtype followed by Tukey’s test for pairwise comparison demonstrates statistically 
significant differences in the levels of pathway expression between molecular subtypes. Box 
colors indicate the level of significance between subtypes, as indicated in the legend. NS, not 
significant. 
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Figure 3.2 Correlation between calculated pathway activity. A Pearson correlation matrix of 
each signature versus all other signatures (including itself as the diagonal line) demonstrates a 
high degree of concordance amongst independently developed gene expression signatures 
measuring similar or associated pathways. Red indicates high positive correlation and blue a 
strong anti-correlation. 
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Figure 3.3 Identification of pathway-specific copy number alterations by Spearman Rank 
Correlation. A Spearman rank correlation, both positive (red) and negative (blue) were used to 
identify associations between predicted genomic signature pathway activity and gene-level DNA 
copy number content (n=476).  The negative log10 Bonferroni adjust p-values are plotted 
according to chromosomal position. Chromosomal borders are delineated by vertical black lines. 
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Figure 3.4 Identification of pathway-specific copy number alterations based on frequency of 
gains or losses calculated by Fisher’s Exact test. A Fisher’s exact test was used to calculate the 
statistical significance of the frequency of copy number gains (red) or losses (blue) in samples 
with the highest (top quartile) pathway signature activity relative to all other samples (n=476).  
The negative log10 Bonferroni adjust p-values are plotted according to chromosomal position. 
Vertical black lines indicate chromosomal borders. 
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Figure 3.5 Identification of genomic pathway–specific CNAs. (a) Schematic outlining the 
strategy used to identify CNAs associated with pathway activity. Gain/loss indicates gains or 
losses; Pos/Neg indicates positive or negative. (b) For each signature, significant copy number 
gains and losses were calculated. The plot identifies those genes that had a positive Spearman 
rank correlation and increased amplification frequency (q < 0.01) (red) and those that had a 
negative Spearman rank correlation and an increased frequency of copy number losses in the top-
scoring (top quartile) samples with pathway activity (q < 0.01) (blue). (c–e) Spearman rank 
correlation was used to identify genes positively (black line) or negatively (dark blue) associated 
with pathway activity, and Fisher’s exact test was used to compare the frequency of copy number 
gains (Amp, red) or losses (Del, light blue) for the HER2-AMP (c), HER1-C2 (d) and RB-LOH 
(e) signatures. Yellow arrowheads indicate known pathway drivers with q < 0.01 for each 
analysis; the black arrowhead indicates q < 0.01 for a single analysis. In each figure, 
chromosomal boundaries are indicated by vertical black lines.  
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Figure 3.6 Identification of essential genes amplified in highly proliferative luminal tumors. (A) 
Schematic outlining the integrated genomic strategy to identify essential genes amplified in 
highly proliferative luminal breast tumors. (B) Identification of 21 genes in amplified loci that 
are unique to highly proliferative luminal tumors and are specifically required for luminal cell 
line proliferation in vitro. mRNA expression of genes in red and blue were significantly 
associated with CNA status, with the subset highlighted in red being further validated in the 
METABRIC dataset; genes in black do not show a significant mRNA-DNA correlation. 
Candidate genes demarcated by (*) are located at cusp of a CNA segment and were originally 
excluded, but mentioned here. Genes identified by (#) were not included on mRNA expression 
microarrays, and the correlation between DNA and mRNA expression was not assessed. 
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Figure 3.7 Patterns of pathway activity correspond with molecular subtypes of breast cancer. 
Analysis of molecular subtypes of breast cancer based on 52 gene expression signature scores. 
Euclidean distance was used to calculate the relationship between samples based on scores of 52 
gene express signatures. Samples are commonly ordered on the X and Y axis according to 
molecular subtype. These results demonstrate high concordance within a subtype (dark blue), 
and lower concordance across subtypes; each sample versus itself is the blue diagonal line  
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Figure 3.8 Identification of DNA copy number alterations in highly proliferative breast tumors. 
(A) Distribution of proliferation scores across all tumors and (B) by subtype. (B) Box and 
whisker plots indicate median score and the upper and lower quartile. Basal-like (n=88), HER2E 
(n=55), LumA (n=214) and LumB (n=119). (C) Highly proliferative tumors (top quartile) are 
comprised of Basal-like (49.6%), LumB (33.6%) and HER2E (16.8%). (D) Highly proliferative 
luminal tumors are restricted to LumB (68.0%) and HER2E (32.0%) samples. (E) Frequency of 
CNA in highly proliferative (black line) and all other samples (gray line). (F) Statistical analyses 
of CNA: positive correlation (black) and negative (dark blue) Spearman rank correlation and 
Fisher’s exact test of amplification (red) or deletion (light blue) frequency. (G) Frequency of 
CNA in highly proliferative luminal tumors; color key same as (E). (H) Statistical analyses of 
CNA in proliferative luminal tumors; color key same as (F). Chromosomal boundaries in (E–H) 
are defined by vertical black lines. 
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Figure 3.9 Patterns of pathway activity in human breast cancer cell lines. The scored pathway 
activity for a panel of 51 breast cancer cell lines (GSE12777) was calculated for the 52 pathway 
signatures. Of these cell lines, 27 which are denoted by black squares in lower panel were 
subjected to a genome-wide RNAi screen. 
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Figure 3.10 Identification of genomic pathway-associated essential genes in cell lines. (A) 
Schematic outlining strategy used to identify pathway-specific genetic dependencies. (B) A panel 
of 27 breast cancer cell lines with both expression data and data from a genome-wide RNAi 
screen was used to identify pathway-specific genes required for cell viability using a negative 
Spearman rank correlation (-log10 P-values plotted); significant genes (P<0.05) are shown 
according to chromosome location. Vertical black lines indicate chromosomal boundaries. (C) 
ESR1 (D) ERBB2 and (E) STAT1 or JAK3 shRNA levels are inversely associated with the ER, 
Her2 or Stat1pathway scores. 
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Figure 3.11 Identification of essential genes in proliferative breast cancer cell lines. 
Identification of genes essential for cell viability in vitro in the context of the 11-gene PAM50 
Proliferation signature in (A) all cell line samples and (B) in luminal and HER2+ breast cancer 
cell lines. The negative log10 Spearman rank correlation p values are plotted for each gene 
relative to chromosomal position. 
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Figure 3.12 Correlation between candidate gene mRNA expression and DNA copy number 
status in TCGA samples. The mRNA expression levels of the 21 identified candidate genes that 
are required for cell viability and are uniquely amplified in highly proliferative luminal breast 
tumors. In each plot, the mRNA levels from the TCGA data are compared in those tumors with 
amplifications versus all others.  Of the 21 genes, two (ANKRD56 and TMEM189) were not 
present on the mRNA expression array and are not included here. Of the remaining 19 genes, 12 
had a significant relationship (p<0.05) between copy number status and mRNA expression 
levels. 
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Figure 3.13 Correlation between candidate gene mRNA expression and DNA copy number 
status in METABRIC samples. The mRNA expression levels of the 12 identified candidate genes 
that are required for cell viability and are uniquely amplified in highly proliferative luminal 
breast tumors were analyzed within the context of copy number level in the METABRIC dataset.  
Of these 12 genes, three (SNX21, ZBTB46 and DNAJC5) were not present on both of the 
METABRIC data platforms (mRNA expression and copy number). Of the remaining 9 genes, all 
had a significant relationship (p<0.05) between copy number status and mRNA expression levels 
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Figure 3.14 Validation of increased candidate gene copy number status in highly proliferative 
luminal breast tumors in METABRIC samples. The relationship between amplification of each 
candidate gene within the context of highly proliferative luminal breast tumors was examined in 
the METABRIC dataset. Of the nine candidate genes, eight showed a significant enrichment in 
highly proliferative (top quartile) luminal breast tumors.  
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Figure 3.15 Candidate gene expression correlation with PAM50 Proliferation score independent 
of copy number status. The relationship between mRNA expression and the PAM50 proliferation 
signature was determined independent of copy number status (t-test) in the TCGA (n=388) and 
METABRIC (n=1,333) luminal/ ER+ subset of patients. Three classes of genes were identified 
(top rows) those that have a positive correlation with the signature score irrespective of CN 
status (EIF2S2, EIF6, MRPS23, CPT1A), those that have an inverse correlation (DTX3) and 
those that do not show a consistent pattern between datasets (FGD5, METTL6, SLC2A10) 
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Figure 3.16 Candidate gene amplification correlates with a poor prognosis. Amplification of (A) 
FGD5 (NAMP=51, NNoAMP=337), (B) METTL6 (NAMP=51, NNoAMP=337), (C) DTX3 
(NAMP=71, NNoAMP=317) and (D) MRSP23 (NAMP=127, NNoAMP=261) correlated with 
poor disease-specific outcome in the luminal breast cancer patients in the TCGA dataset (n=388) 
while (E) CPT1A (NAMP=111, NNoAMP=277) amplification had no effect on prognosis. 
Consistent results were observed in the METABRIC dataset (n=1,333) for (F) FGD5 
(NAMP=42, NNoAMP=1,218), (G) METTL6 (NAMP=44, NNoAMP=1,278), (H) DTX3 
(NAMP=67, NNoAMP=1,266), (I) MRPS23 (NAMP=266, NNoAMP=1,062) and (J) CPT1A 
(NAMP=241, NNoAMP=1,029). Samples in the METABRIC dataset missing CNA calls were 
excluded. For each analysis, P-value determined by log-rank test and Hazard Ratio (HR) are 
reported. 
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Figure 3.17 Amplification status of a subset of candidate genes has no reproducible effect on 
prognosis. Kaplan-Meier survival analysis based upon the amplification status of highly 
proliferative luminal tumor genes. No consistent difference in disease specific survival was 
observed for EIF2S2 (A, D), EIF6 (B, E) or SLC2A10 (C, F) when comparing luminal tumors 
characterized by amplification of each candidate gene relative to luminal tumors without an 
amplification (log rank p>0.05) in the TCGA (A-C) and METABRIC (D-F) datasets.   
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CHAPTER 4 
LOSS OF HETEROZYGOSITY AT THE CYP2D6 LOCUS IN BREAST CANCER: 
IMPLICATIONS FOR GERMLINE PHARMACOGENETIC STUDIES2 
 
 
 Background: Controversy exists regarding the impact of CYP2D6 genotype on tamoxifen 
responsiveness. We examined loss of heterozygosity (LOH) at the CYP2D6 locus and 
determined its impact on genotyping error when tumor tissue is used as a DNA source.  
 Methods: Genomic tumor data from the adjuvant and metastatic settings (The Cancer 
Genome Atlas [TCGA] and Foundation Medicine [FM]) were analyzed to characterize the 
impact of CYP2D6 copy number alterations (CNAs) and LOH on Hardy Weinberg equilibrium 
(HWE). Additionally, we analyzed CYP2D6 *4 genotype from formalin-fixed paraffin-
embedded (FFPE) tumor blocks containing nonmalignant tissue and buccal (germline) samples 
from patients on the North Central Cancer Treatment Group (NCCTG) 89-30-52 tamoxifen trial. 
All statistical tests were two-sided.  
 Results: In TCGA samples (n =627), the CYP2D6 LOH rate was similar in estrogen 
receptor (ER)–positive (41.2%) and ER-negative (35.2%) but lower in HER2-positive tumors 
(15.1%) (P < .001). In FM ER+ samples (n = 290), similar LOH rates were observed (40.8%). In 
190 NCCTG samples, the agreement between CYP2D6 genotypes derived from FFPE tumors
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and FFPE tumors containing nonmalignant tissue was moderate (weighted Kappa = 0.74; 95% 
CI = 0.63 to 0.84). Comparing CYP2D6 genotypes derived from buccal cells to FFPE tumor 
DNA, CYP2D6*4 genotype was discordant in six of 31(19.4%). In contrast, there was no 
disagreement between CYP2D6 genotypes derived from buccal cells with FFPE tumors 
containing nonmalignant tissue.  
 Conclusions: LOH at the CYP2D6 locus is common in breast cancer, resulting in 
potential misclassification of germline CYP2D6 genotypes. Tumor DNA should not be used to 
determine germline CYP2D6 genotype without sensitive techniques to detect low frequency 
alleles and quality control procedures appropriate for somatic DNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 !
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INTRODUCTION 
 The CYP2D6 enzyme metabolizes tamoxifen to its active metabolites (4-hydroxy-
tamoxifen and 4-hydroxy-N-desmethyl-tamoxifen [endoxifen]), and numerous studies have 
demonstrated that CYP2D6 genetic variants are associated with steady state endoxifen 
concentrations [1–2]. However, there is substantial controversy on the validity of CYP2D6 
genotype as a predictor of benefit from tamoxifen therapy in the adjuvant setting (reviewed in 
[3]). Secondary analyses of adjuvant trials administering five years of tamoxifen (the North 
Central Cancer Treatment Group [NCCTG] 89-30-52 [4], Arimidex, tamoxifen, alone or in 
combination (ATAC) [5], BIG1-98 [6], and the Austrian Breast and Colorectal Cancer Study 
Group [ABCSG] 8 [7] have reached discrepant conclusions). Multiple investigators have voiced 
concern regarding the unprecedented departure of CYP2D6 allele frequencies from Hardy- 
Weinberg equilibrium (HWE) in the BIG 1-98 study [8–10]. While substantial departure from 
HWE was not observed in the ABCSG 8 analysis [7], some departure from HWE was observed 
with the CYP2D6*4 allele frequencies reported in the NCCTG 89-39-52 [4] and ATAC [5, 9] 
CYP2D6 analyses. Given previous demonstration of genomic instability at the chromosomal 
segment where CYP2D6 is located [11–12], it has been hypothesized that when tumor DNA is 
used for genotyping, the presence of tumor loss of heterozygosity (LOH) at the CYP2D6 locus 
distorts the frequencies of observed alleles, which could lead to an excessive homozygous 
assignment of the germline genotype [8–10]. To address this question, we undertook a detailed 
evaluation of whether somatic LOH occurs at the CYP2D6 locus by analyzing genomic tumor 
data from the adjuvant (The Cancer Genome Atlas [TCGA]) [13] and metastatic settings. 
Furthermore, we sought to determine whether CYP2D6 LOH could affect the accuracy of calling 
germline CYP2D6 genotypes. Finally, in a limited number of adjuvant cases in which both 
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formalin-fixed paraffin-embedded (FFPE) tumor blocks and buccal samples were available, we 
compared CYP2D6 *4 genotypes obtained from each DNA source.  
 
MATERIALS AND METHODS 
 Samples. Three previously published data sets were analyzed. The first data set included 
tumors collected and annotated within The Cancer Genome Atlas breast dataset [13]. TCGA 
collected breast tumors from newly diagnosed patients who underwent surgical resection. 
Extensive quality control was employed to verify the presence of both tumor DNA and germline 
DNA. Briefly, each frozen primary tumor specimen had a companion normal tissue DNA 
specimen that was derived from blood components (including DNA extracted at the tissue source 
site) (n = 684), adjacent normal tissue taken from greater than 2 cm from the tumor (n = 76), or 
both (n = 65). Each hematoxylin and eosin (H&E) stained case was reviewed by a board-certified 
pathologist to confirm that the tumor specimen was histologically consistent with breast 
adenocarcinoma and the adjacent normal specimen contained no tumor cells. The tumor sections 
were required to contain an average of 60% of tumor cell nuclei with less than 20% necrosis for 
inclusion in the study per TCGA protocol requirements. The clinical characteristics of this cohort 
and the process for informed consent have been previously described [13].  
 The second set included paraffin-embedded blocks from 360 patients, with relapsed and 
metastatic ER+ (n = 261) or ER- (n = 99) breast cancers derived from a subset of patients from 
the NCT00780676 trial and from pathology departments of several medical centers, as recently 
described [14]. From these samples, CYP2D6 sequencing was performed by Foundation 
Medicine (FM). In addition, samples were stained for ER, progesterone receptor (PR), and 
human epidermal growth factor receptor–2 (HER2) and reviewed by a pathologist to confirm ER 
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positivity. All tissue collections were done with the approval of the corresponding institutional 
review boards, and the process for informed consent was previously published [14].  
 The third set included specimens from 190 ER-positive breast cancer case patients from 
the NCCTG 89-30-52 clinical trial [4]. In the initial reported CYP2D6 analysis, an H&E section 
was obtained from FFPE tumors and a board-certified pathologist identified the invasive 
component and DNA was extracted from a 1 cm area of highest tumor cellularity for both DNA 
[4] and RNA [15] studies. At a later date, the same tissue block was accessed and whole tissue 
sections containing both invasive and benign tissue were processed for DNA extraction as 
previously described [16–17]. Additionally, germline DNA from a buccal sample was collected 
and reported initially on 17 patients [4] and an additional 21 patients later provided buccal 
samples. All tissue collections were done with the approval of the corresponding institutional 
review boards, and the process for informed consent was previously published [4]. 
 Genomic Analysis. For the TCGA cohort, DNA copy number at the CYP2D6 locus 
(Chr. 22: 42 522 501 – 42 525 911) was determined using the Affymetrix 6.0 single-nucleotide 
polymorphism (SNP) arrays [13] and copy number segmentation was performed using the 
Circular Binary Segmentation (CBS) algorithm version 1.12.0, as previously described [13]. 
Copy number segments of interest were identified as regions with intensity values greater than 
|0.3|. Frequency landscape plots of these segments were created using the SWITCHdna R-
package plotting function [18]. Exome sequencing was performed as previously described [13]. 
Regions of LOH were identified using the Broad Institute’s ABSOLUTE method on exome 
sequencing data and Affymetrix 6.0 SNP arrays [19]. LOH landscape frequency plots were 
created using modifications of SWITCHdna’s plotting function. The percentage of overlap 
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between breast TCGA samples analyzed on SNP arrays and those through exome sequencing 
was 86%.  
 For the FM cohort, genomic DNA was extracted from 40 )m of FFPE tissue and up to 
200ng of extracted DNA was sheared by sonication, followed by ligation of Illumina sequencing 
adaptors. Sequencing libraries were hybridization captured using RNA-based baits (Agilent), 
targeting a total of 3320 exons of 182 cancer-related genes and 78 polymorphisms in 34 ADME-
related genes. Deep (>500x) paired-end sequencing (49 x 49 cycles) was performed using the 
HiSeq2000 (Illumina). Sequence reads were mapped to the reference human genome (hg19), 
analyzed for all classes of genomic alterations (substitutions, indels, and copy number 
alterations), using custom methods optimized for clinical tumor specimens with stromal 
admixture. Variant calls at the CYP2D6 locus were resolved into genotypes according to the star 
(*) allele nomenclature [20]. If the minor allele frequency was greater than 5%, the patient was 
considered to have germline heterozygosity. To determine tumor LOH at CYP2D6, a genome-
wide copy number model was fitted to the coverage data at all sequenced exons and more than 
1800 SNPs. This profile was segmented and interpreted using allele frequencies of sequenced 
SNPs to estimate tumor purity and copy number at each segment. Fitting was performed using 
Gibbs sampling, assigning total copy number and minor allele count to all segments. LOH was 
called if total copy number at the CYP2D6 locus was 1 (copy loss LOH), or if copy number was 
2 or more with a minor allele count of 0 (copy neutral LOH). The distortion of the germline 
alternate allele frequency from 50% because of LOH is calculated. To assess the impact of LOH, 
we simulated low-sensitivity genotyping assays by requiring minor allele frequencies to have 
minimum levels of 10% and 20% before assigning genotypes as heterozygous. The estimate of 
potential error impact on genotyping methods was then estimated using the HWE test.  
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 For the NCCTG samples, CYP2D6 genotyping (*3, *4, *6, *10, *41) was performed at 
the Mayo Clinic using the Applied Biosystems’ Taqman Allelic Discrimination Assay (Foster 
City, CA), as previously described and reported in the context of a pooled analysis of NCCTG 
and Stuttgart patients [16] and as submitted to the International Tamoxifen Pharmacogenomics 
Consortium [21]. Analyses were performed irrespective of ethnicity. 
 Statistical Methods. Within the TCGA, a Pearson’s Chi Square Test was used to 
determine whether LOH rates differed across intrinsic subtypes. Within the FM cohort, a two-
sided Fisher’s exact test was used to assess whether copy loss rate differed with respect to ER 
status. Within the NCCTG cohort, the extent of agreement between CYP2D6 genotypes derived 
from FFPE tumor and FFPE tumors containing nonmalignant tissue was assessed using weighted 
Kappa statistics and the corresponding 95% confidence interval. HWE tests were calculated 
using an exact test (the Simple Hardy-Weinberg Calculator by Michael H Court) (http://www. 
tufts.edu/~mcourt01/Documents/Court%20lab%20-%20HW%20 calculator.xls) by comparing 
the observed and expected genotype frequencies for case patients and control patients. All 
statistical tests were two-sided, and a P value of less than .05 was considered statistically 
significant. 
 
RESULTS 
TCGA Samples 
 Using SNP array data (n = 728) [13], evaluation of the CYP2D6 locus at chromosome 22 
demonstrated copy number alterations (CNA) in 29.0% (n = 211) (Figure 4.1A). Among the 627 
case patients with exome sequencing data, 219 case patients (34.9%) had LOH at the CYP2D6 
locus (Figure 4.1B). While the CNA were higher for the ER-positive (35.0%) (Figure 4.2A) 
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compared with the ER-negative (12.0%) (Figure 4.2B), LOH rates were similar comparing ER-
positive (41.2%) (Figure 4.3A) and ER-negative (35.2%) (Figure 4.3B). Analyzing according to 
intrinsic subtypes, LOH rates among the ER+ (luminal A [40.3%] luminal B [42.7%]) and basal- 
like (43.4%) subsets were similar but greater than that in the HER2-enriched subtype (15.1%) (P 
< .001, Pearson’s Chi Square Test). For each of these subtypes, a “zoomed-in plot” of the region 
containing the CYP2D6 gene is indicated (Figure 4.4 and Figure 4.5). A further analysis within 
the clinically defined HER2+ subset demonstrated that LOH rates were lower within the ER-
/HER2+ (14.3%) compared with ER+/ HER2+ (26.6%). 
 
Foundation Medicine Samples 
 The findings among the case patients comprising the FM cohort were similar to those 
from the TCGA cohort, where 82 of 201(40.8%) and 23 of 89 (25.8%) of the ER+ and ER- case 
patients, respectively, had LOH at the CYP2D6 locus (Figure 4.6). While copy- neutral LOH 
was similar in both ER+ and ER- (18.9% and 19.1%, respectively), the copy loss rate among 
ER+ case patients was statistically significantly greater relative to ER- case patients (21.9% vs 
6.7%; P = .001, two-sided Fisher’s exact test). Given that standard genotyping assays (eg, 
Taqman) may not be able to detect an allele that is present at low frequency because of LOH, 
CYP2D6 genotypes were determined using next generation sequencing (Table 4.1) and the 
potential effect of LOH on CYP2D6 genotype was assessed (Table 4.2). Among the 105 case 
patients with LOH, a substantial fraction had a low frequency of one of the germline alleles: 
under 20% (n = 27), under 10% (n = 7). If such samples were assumed to be homozygous, this 
would result in excessive number of homozygotes and, statistically, departure from HWE (Table 
4.2). 
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NCCTG 89-30-52 Samples 
 The original CYP2D6 *4 genotyping results were derived from tumor FFPE (FFPE-T) 
and demonstrated departure from HWE (chi square = 16.1, P * .001) [4]. These case patients (n 
= 190) were reassessed using FFPE sections containing nonmalignant tissue (FFPE-NM) [16]. 
For CYP2D6 *4, the agreement was moderate comparing CYP2D6 *4 genotypes derived from 
FFP-T with FFPE-NM (weighted Kappa 0.74; 95% CI = 0.63 to 0.84), resulting in excess 
homozygous genotypes and departure from HWE (P < .001). Specifically, 15 original 
homozygous wild-type (Wt/Wt) cases were reclassified as heterozygous for *4 (Wt/*4) and three 
homozygous variant (*4/*4) were reclassified as (Wt/*4). The *4 discrepancies among the 
remaining five cases were likely unexplained by LOH (Table 4.3). An evaluation for HWE using 
the genotyping data derived from FFPE-NM demonstrated that CYP2D6*4 is within HWE (chi 
square = 1.34, P = .25).  
 To further investigate the observed discrepancy between these results, the CYP2D6 
genotypes derived from FFPE-T tumor [4] and FFPE-NM [16] were compared with CYP2D6*4 
genotype derived from buccal cells (germline). Among the 31 case patients with both FFPE-T 
and buccal cells available for CYP2D6*4 genotyping, there were six (19.4%) cases of 
disagreement. In four of these six case patients, CYP2D6 *4 genotypes classified as homozygous 
wild-type using FFPE-T were determined to be heterozygous for *4 (Wt/*4) using DNA derived 
from buccal cells, and, in another case, a homozygous variant (*4/*4) based on FFPE-T was 
classified as (Wt/*4) using DNA from buccal cells. One of the errors appeared to be unrelated to 
LOH, as the tumor-derived genotype of *4/*4 was classified as Wt/Wt using buccal cells. In 
contrast, among the 35 case patients with DNA from both FFPE-NM and buccal cells, there was 
100% agreement comparing CYP2D6 *4 genotypes from each source. 
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DISCUSSION 
 Using two large breast cancer datasets, we have demonstrated the presence of extensive 
LOH at the CYP2D6 locus in breast cancer. Furthermore, our data demonstrate that 
determination of germline CYP2D6 genotype using cancer tissue can result in substantial 
departure from HWE, as was seen in the original NCCTG CYP2D6 analysis [4], ATAC [5], and 
BIG 1-98 [6] studies. In the cohorts examined in this study, CYP2D6 genotyping using DNA 
extracted from FFPE-T blocks resulted in erroneous classification of up to 40% of CYP2D6*4 
heterozygotes (intermediate metabolizers) as either extensive metabolizers or poor metabolizers.  
 Recently, Rae et al., in a cohort of 122 patients, extracted DNA from three 0.6-mm 
diameter cores obtained from FFPE breast tumor blocks as well as DNA derived from either 
normal lymph nodes or leukocytes [22]. Rae et al. used DNA from these sources to genotype for 
CYP2D6 and demonstrated a concordance rate of over 94% between these different sources, 
concluding that this modest quality control study was sufficient to support the use of breast 
cancer tissue for germline genotyping of CYP2D6 [22]. The results of our studies in this report 
clearly refute the conclusions of Rae and colleagues and provide further confirmation of the 
concerns raised by multiple authors [8–10] regarding the fidelity of the CYP2D6 genotyping 
performed in the context of the BIG 1-98 study [6]. 
 Quality control procedures are critical for accurate genotyping. This includes a 
requirement to develop assays for all relevant variants, particularly for a locus as complex as 
CYP2D6 [23]. An additional critical aspect of quality control relates to the source of DNA used 
for germline genotyping. In ATAC [5], FFPE tumor blocks from the trans-ATAC tumor 
collection were used for DNA extraction. In BIG 1-98 [6], DNA was extracted from one or two 1
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mm cores that were punched into an area of the FFPE block most representative of the invasive 
tumor component.  
 Given our observation of LOH at the chromosomal locus containing CYP2D6, it was 
critical to understand whether the use of tumor DNA could contribute to the observed departures 
from HWE. In the FM cohort, nearly one-third of the tumors with LOH had a frequency of the 
germline allele under 20%, suggesting that use of a low-sensitivity polymerase chain reaction 
(PCR) assay could result in misclassification of heterozygous CYP2D6 genotypes as 
homozygous. Therefore, we directly compared CYP2D6 genotyping results from different 
laboratories using DNA from the same patients. In the original publication of the NCCTG 89-30-
52 clinical trial, CYP2D6 genotyping (using DNA extracted from tumors) was performed in the 
laboratory of Rae et al. at the University of Michigan [4]. When CYP2D6 genotyping was 
repeated at the Mayo Clinic using DNA derived from the same FFPE blocks but using whole 
tissue sections containing benign tissue, genotyping errors were identified, which appeared to be 
partially related to the lack of detection of low-frequency alleles in the 2005 analysis; however, 
additional discrepancies were observed that appear to be unrelated to LOH (Table 4.3). A full 
reanalysis of the NCCTG data set demonstrated that CYP2D6 genotypes met HWE, with 
complete agreement (35/35) between the updated genotype results with the germline (buccal) 
cells in those patients that provided a buccal sample. Furthermore, as previously reported, 
CYP2D6 genotype was statistically significantly associated with the risk of recurrence [16, 21].  
 In ATAC [5], the departure from HWE with regard to CYP2D6 *4 was similar in 
magnitude as observed in the original NCCTG CYP2D6 analysis (HWE +2 = 18.1, P = .000021). 
While we are confident in our conclusions that LOH at the CYP2D6 locus is common in breast 
cancer and that the use of tumor DNA for CYP2D6 genotype results in misclassification of 
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germline CYP2D6 genotype, we were unable to reproduce the extreme departure from HWE 
observed in BIG 1-98 (P = 10-92 ) [6]. Stanton noted that if LOH was the sole cause of deviation 
from HWE in BIG 1-98, the distorted genotype frequencies could be normalized by adjusting for 
LOH [9]. Therefore, we agree with Stanton that the extreme departure from HWE in BIG 1-98 
may be related to other factors, such as the use of nonstandard PCR techniques (use of upwards 
of 60 PCR cycles) [6].  
 Following the simultaneous publication of the CYP2D6 analyses of the ATAC and BIG 
1-98 data sets, the authors of these studies argued that testing for CYP2D6 has no value in 
clinical practice, and an accompanying editorial concluded that this matter can be likely laid to 
rest [24]. However, our findings have validated the initial concerns raised by multiple 
investigators regarding genotyping error [8–10] and the conclusions that were generated based 
on these erroneous data. It is now clear that data from ongoing prospective clinical trials will be 
necessary to settle the debate on whether or not CYP2D6 genotyping can identify patients in 
whom tamoxifen would be would be an inferior therapy. However, until such data are available, 
clinicians and patients should be aware of the data generated from secondary analyses of 
prospective clinical trials that support the importance of both CYP2D6 genotype [7, 16] and 
endoxifen concentrations [25] and that these data fulfill the basic criteria of Simon et al. for a 
“prospective-retrospective” design in which the biomarker test is analytically and preanalytically 
validated for use with archived tissue [26].  
 An important finding within the TCGA CYP2D6 analysis was the observation of a 
substantially higher rate of LOH within the luminal A (40%), luminal B (43%), and basal-like 
subsets (40%), compared with the HER2-enriched (15%) and normal-like (8%) subtypes. Within 
the clinically defined HER2+ subset, LOH rates were lower within the ER-/HER2+ (14%) 
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compared with ER+/ HER2+ (27%). Within the FM cohort, the CYP2D6 loss rate among ER+ 
case patients was statistically significantly greater relative to ER- case patients While the 
biological relevance of these findings is unknown, the demonstration of substantial LOH at 
chromosome 22q13, the cytogenetic segment which contains the CYP2D6 gene, has been 
implicated in breast [11], colon [11, 27], and insulinomas [28], suggesting that a putative tumor 
suppressor gene in this region may be important in the pathogenesis of cancer, and particularly in 
the luminal and basal-like subtypes of breast cancer. 
 There are some limitations to our study. While we have demonstrated that the use of 
tumor-derived DNA contributes to CYP2D6 genotyping error (analytical validity), this is 
unlikely to be the only factor contributing to the heterogeneity in the tamoxifen CYP2D6 
literature. In addition to “analytical validity,” Simon et al. pointed out that an “adequate number 
of patients with archived tissue must be present,” and suggested that the correlative study 
“include at least two-thirds of the total accrued patients” [26]. It should be noted that in the 
ATAC study, less than 19% of the patients receiving tamoxifen were analyzed with regard to 
CYP2D6 genotype. Lastly, Simon et al. pointed out the critical nature of “clinical validity” [26]. 
Here, it should be noted that the tamoxifen CYP2D6 literature contains variability in tamoxifen 
dosing (20-40 mg/day), duration of therapy (one to 10 years), ER status of the primary tumor, 
use of CYP2D6 inhibiting medications, and, finally, lack of control for drugs that alter the hazard 
for recurrence (chemotherapy and aromatase inhibitors) [21]. Therefore, we recommend careful 
control for each of these factors when analyzing and interpreting the tamoxifen CYP2D6 
literature.  
 In summary, we have provided definitive data from independent data sets that over 40% 
of primary and metastatic breast tumors exhibit tumor LOH at the CYP2D6 locus and that the 
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use of standard PCR (eg, Taqman) genotyping techniques applied to purified tumor DNA to 
detect germline CYP2D6 variation results in genotyping error because of an excess number of 
homozygotes and departure from HWE. Based on these results, we recommend that CYP2D6 
genotyping be repeated in those studies in which the use of tumor DNA to derive germline 
CYP2D6 genotype resulted in substantial departure from HWE. Furthermore, recommendations 
and/or guidelines for the use of CYP2D6 genotyping should not be derived from studies with 
evidence for genotyping error.  
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CYP2D6 allele   Enzyme activity Count in FM 
cohort 
Frequency in 
FM cohort, % 
Expected 
frequency, 
% (20) (for 
Europeans) 
*1 or *2 Normal (wild-type) 461 64.0 63.1 
*4  None 120 16.7 17.2 
*41 Reduced 65 9.0 7.0 
*9  Reduced 15 2.1 2.5 
*10  Reduced 14 1.9 2.9 
*5(deletion of allele) None 11 1.5 3.2 
*6 None 7 1.0 0.6 
 *29 Reduced 7 1.0 0 
*3  None 6 0.8 0.3 
*17 Reduced 4 0.6 0 
Other rare alleles Various 10 1.4 0.4 
Tandem duplications Increased  Not assessed  Not assessed 2.8 
* CYPD6 = cytochrome P450 2D6; FM = Foundation Medicine; NGS = next generation 
sequencing. !!!
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 CYP2D *4 genotype using 
DNA from tumors containing 
benign tissues (16) 
 
CYP2D6 *4 genotype 
using tumor-enriched 
DNA(4) 
Wt/Wt Wt/*4 *4/*4 No call on 
updated 
analysis 
Total 
Wt/Wt 121 15 1   
Wt/*4  2 34 0   
*4/*4 2 3 8   
Total 125 52 9   
* CYPD6 = Cytochrome P450 2D6; FFPE = formalin-fixed paraffin-embedded; Wt = 
wild-type. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 !
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FIGURES 
 
 
 
Figure 4.1 Cytochrome P450 2D6 (CYP2D6) copy number alterations (A) and loss of 
heterozygosity (B) within the entire Cancer Genome Atlas cohort. CNA = copy number 
alteration; LOH = loss of heterozygosity. 
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Figure 4.2. Cytochrome P450 2D6 (CYP2D6) copy number alterations within The Cancer 
Genome Atlas estrogen receptor (ER)–positive (A) and ER-negative (B) cohorts. CNA = copy 
number alteration; ER = estrogen receptor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! %*.!
 
 
Figure 4.3 Cytochrome P450 2D6 (CYP2D6) loss of heterozygosity within The Cancer Genome 
Atlas estrogen receptor (ER)–positive (A) and ER-negative (B) cohorts. ER = estrogen receptor; 
LOH = loss of heterozygosity. 
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Figure 4.4 Cytochrome P450 2D6 (CYP2D6) Loss of Heterozygosity (LOH) rates according to 
intrinsic subtypes:  Luminal A (A), Luminal B (B) within The Cancer Genome Atlas (TCGA) 
samples.  The CYP2D6 gene is indicated by a yellow line. 
 
 
 
 
 
 
 
 
! %*'!
 
 
Figure 4.5 Cytochrome P450 2D6 (CYP2D6) Loss of Heterozygosity (LOH) rates according to 
intrinsic subtypes Basal (A) and HER2 (B) within The Cancer Genome Atlas (TCGA) samples.  
The CYP2D6 gene is indicated by a yellow line. 
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Figure 4.6 Frequency of Cytochrome P450 2D6 (CYP2D6) loss of heterozygosity within the 
Foundation Medicine estrogen receptor (ER)–positive (A) and ER-negative (B) cohorts. Tumor 
LOH is denoted in red. ER = estrogen receptor. 
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CHAPTER 5 
CONCLUSION 
 
 
 Numerous hallmarks of cancers have been proposed including sustaining proliferative 
signaling, activating metastasis and invasion, evading growth suppressors, resisting cell death, 
and inducing angiogenesis [1].  The function of these hallmarks are fostered, and at times 
accelerated, by genomic instability. In tumors, increases in genomic instability and aneuploidy 
are usually associated with poor patient prognosis. Early on, the focus of copy number analyses 
research favored whole arm/whole chromosome changes that were traditionally studied by 
spectral karyotyping. However, using high-density arrays, this work demonstrated that many of 
the sub-chromosomal changes, which are less characterized, are also significant and detrimental 
in complex human disease. Understanding how DNA Copy Number Alterations (CNAs) promote 
disease is an important challenge and is further complicated by the complexity of cancer. We 
demonstrate that one single strategy, which has normally been presented in copy number 
analyses, is not sufficient to fully understand the role of CNAs in breast cancer progression. 
 In breast cancer, numerous genetic alterations have been identified and demonstrate 
clinical implications, with the best example being the biological and clinical importance of 
HER2 amplification. We highlighted another class of potential drivers that have yet to be 
established in the clinical setting. This copy number based approach identified targets that were 
rarely mutated, and drivers where the genetic alteration is used as a mechanism for differential
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gene expression and cellular changes. In addition, we demonstrated that numerous genes could 
be targeted by a single alteration, where in essence a given amplification in fact has at least three 
driver genes as opposed to the more conventional expectation that a given CNA has a single 
target gene. More importantly, we demonstrated that a single alteration could lead to disruptions 
of multiple pathways with similar, or diverse, downstream biological processes that promote the 
cancer phenotype. These findings support the use of combinatorial-targeted drug therapies and 
can further help in the development of new ‘personalized’ cancer treatment options.  
 Previous studies have demonstrated the heterogeneity of breast cancers, and used 
histopathological features as prognostics for clinical outcomes. More recently, various 
molecular-profiling methods are used to identify and characterize new clinically relevant 
features. The increase in high-throughput molecular data from cancer-profiling projects using 
microarrays (and now next-generation sequencing) platforms creates great research 
opportunities, but also significant computational challenges for analysis and interpretation. These 
challenges emphasized the necessity of integrative analyses, and the need to investigate multi-
dimensional interactions across multi-level ‘-omics’ data types. For example, integrative 
analyses can incorporate data from different sample types (i.e. germline DNA genotypes, tumor, 
or model system samples), different disease states (i.e. normal or malignant), and multi-level 
classified data that may include histopathology, genetics, transcriptomics and/or proteomics 
features.  
 Given the growing importance of integrative analyses, it was also important to point out 
necessary caveats. From a statistical perspective, as we increased the dimensionality in the 
analyses we also increased the amount of unknown parameters. Therefore, we selected data 
where the underlying relationships between the levels are known (i.e. similar copy number 
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changes are present and spontaneously occurring cross-species). Furthermore, various 
normalization steps were performed, including numerous data checks to test and correct for 
platform batch effects, and to adjust the data to the same scale (both technically or biologically). 
From a biological perspective, this work demonstrated that multiple potential drivers can exists 
within a single region of CNA, and as a result, different strategies may identify different drivers 
within the same altered region. 
 The integrative analyses in Chapter 2 showed a novel way to comprehensively compare 
CNAs observed in human breast cancer subtypes and genetically engineered mouse (GEM) 
mammary tumor models. We highlighted regions of shared CNAs between human breast tumors 
and GEM models that also shared similar gene expression features, with a particular emphasis on 
basal-like breast cancers. We demonstrated that there was not a single GEM mammary model 
that shared an overall defining pattern of CNAs with any single human breast intrinsic subtype; 
however, numerous sub-chromosomal commonalities were identified, and were the focus of our 
additional analyses. These analyses incorporated additional functional resources using data from 
a RNAi screen, DNA to RNA correlations, and a DawnRank network analysis [2] to develop a 
comprehensive map of essential breast cancer driver genes on a few selected conserved CNAs. 
Importantly, this work provided a preclinical resource for selecting GEM mammary models for 
therapeutic response testing based upon the genetics shared between human tumors and mouse 
models. 
 Interestingly, the majority of conserved CNAs between humans and mice were identified 
in the Basal-like breast cancer subtype. We suggest this is due to the fact these CNAs are altering 
pathways that promote the Basal-like phenotype such as PIK3CA/AKT and NOTCH signaling 
pathways. Additionally, we demonstrated that chromosome 1 is a rich region of CNAs across all 
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subtypes, especially for the Basal-like subtype. And unlike previous works that could not narrow 
down the driving genes of 1q arm amplification, we’ve highlighted a more target-gene 
concentrated region of 1q21-23 that contains multiple drivers. Here we highlighted PI4KB, 
SHC1, and NCSTN as candidate Basal-like-specific driving genes. These results suggested that 
the strategy presented in Chapter 2 was sensitive enough to identify regions of CNAs that harbor 
multiple drivers within an amplicon while still filtering out “passenger” genes. 
 Another example of using integrative analyses to highlight driving genes within CNAs 
was shown in Chapter 3. In this study, experimentally derived gene expression signatures of 
signaling pathway activity, and a RNAi screen dataset, was used to identify the driver genes 
within CNAs that were associated with high proliferation among luminal/ER+ breast cancers. 
Gene expression signatures provided an essential tool by highlighting patterns of pathway 
deregulation that reflect activation of various oncogenic pathways, like proliferation. Using 
experimentally derived gene-expression signatures, we were able to define subtype-specific 
patterns of oncogenic signaling and identified a novel drug target that regulates fatty acid 
oxidation (i.e. CTP1A).  
 In Chapter 3, we highlighted known characteristics of each subtype such as low hormone 
receptor signaling, mutant p53 signaling and high proliferation activity in Basal-like/triple-
negative breast cancers. In addition numerous significant correlations were highlighted between 
gene expression signatures of shared pathways such as between separate MYC signatures, and 
between PIK3CA and PTEN-deleted signatures. Significant correlations were also observed 
between signatures from separate pathways but that shared similar associations such as EGFR-
mediated activation of STAT3 signaling resulting in the observed concordance between STAT3 
and EGFR signatures.  
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 We highlighted expected finding such as an association between the RB-LOH signature 
and RB1 DNA copy number loss and also with HER2/ERBB2 amplicon and the HER2-AMP 
signature. In addition, we presented many novel correlations, including a set of amplified genes 
associated with the PAM50 proliferation signature [3] that was specific to proliferative luminal 
tumors. This association is particularly interesting as defects in cell-cycle regulation are 
hallmarks of cancer progression. Additional RNAi screen data was used to filter out non-
essential genes in the region highlighting FGD5, METTL6, CPT1A, DTX3, MRPS23, EIF2S2, 
EIF6 and SLCA10 as essential genes, and which also demonstrate prognostic characteristics. 
 Another clinically relevant implication of CNAs analyses was highlighted in Chapter 4. 
In this chapter, we aimed to address the controversy regarding the impact of CYP2D6 genotype 
on tamoxifen responsiveness. Tamoxifen, an effective breast cancer treatment in the subgroup of 
ER+ patients, demonstrates anti-estrogen properties and inhibits estrogen-dependent breast 
cancer growth. As a result, tamoxifen is often used to treat all stages of ER+ breast cancer. The 
most potent metabolite of tamoxifen is produced as a result of a cyotchrome p450 enzymes [4], 
which is encoded by the CYP2D6 gene. Previously, pharmacodynamics studies demonstrated 
varying results as to whether CYP2D6 genotype is associated with a patient’s ability to 
metabolize tamoxifen with the potential high metabolizing variants predicting response, and the 
low tamoxifen metabolizing alleles predicting resistance. 
 This work addressed previous concerns that somatic deletion and/or LOH at CYP2D6 
distorts genotype calls and lead to excessive homozygous assignments, and thus, incorrect 
genotype calls. We evaluated the frequency of LOH and copy number loss across multiple 
cohorts. We identified frequent copy number loss and LOH at CYP2D6 in breast cancer patients 
(~30%). This region of copy number loss was more frequently observed in ER-positive patients 
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(i.e. patients that are offered Tamoxifen therapies) compared to ER-negative, whereas, the rate of 
LOH was comparable across both patient group. In addition, we compared genotyping results in 
the same group of patients across different labs and observed that when tumor DNA was used to 
infer germline CYP2D6 genotype, this resulted in genotyping error and the misclassification of 
some patients which affects whether or not, and potentially at what dose, a patient might receive 
Tamoxifen treatment.  
 In conclusion, my dissertation demonstrated two separate clinical utilities of CNA 
analyses in breast cancer; one includes highlighting driver genes on frequent regions of CNA, 
and the other highlights the effect of CNAs on the genotype calls used to predict a patients’ 
therapeutic responsiveness. The two integrative analyses presented in Chapter 2 and Chapter 3 
were successful in identifying driver genes within regions of CNAs and discovering the 
functional implications of identified CNAs in subtype-specific breast cancer progression. 
However, the analyses highlighted in Chapter 2 and Chapter 3 does share some limitations. In 
both chapters we were confounded by the amount that either mouse models or gene expression 
signatures recapitulate driving human breast cancer features. To validate all potential targets 
identified in these chapters will require new experiments, both at the bench and computationally. 
In some cases published functional analyses were already performed  (i.e. NCSTN in Chapter 2). 
In these cases a comprehensive data-mining approach to match identified genes with relevant 
published functional experiments is feasible and provides for quick functional validation of our 
computational findings.  
 For the cases where published functional information is unavailable, we suggest 
additional biological experiments, which likely include forward genetics (cDNA 
overexpression), or reverse genetic (RNAi or CRISPR) type experiments.  These experiments 
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would likely incorporate breast cancer cell lines such as ME16C, SUM102, SUM149 and MCF7 
to act as a model system. In these experiments, CNAs can be identified as was described in 
Chapter 2 or through publically available resources such as the Cancer Cell Line Encyclopedia 
[5]. Using cell lines, an identified altered gene can be functionally characterized through 
additional experiments that over-expresses the gene, alters the protein function via drug-delivery, 
or compare growth in soft agar (which only cancer cells can do) with and without the gene of 
interest. Any biologically validated genes can then be compared with the clinical outcomes of 
patients who, for example, highly express that given amplified gene, to see if expression and/or 
alteration demonstrate any prognostic or predictive benefits. The work presented provides 
important insights and strategies to understand and characterize the genetic and cellular defects 
that promote the cancer phenotype using a novel analysis of DNA CNAs and a logical 
computational strategy, which can be applied to multiple tumor types. 
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APPENDIX 1 
 
Basal-specific conserved 1q segments of CNAs with frequency >= 15% 
  
Chr Start Stop % Subtype-Specific  Segment Genes CNA Mouse Groups 
1 120315523 144109392 0.35 REG4, ADAM30, NOTCH2 GAIN C3Tag, Myc 
1 144369072 145390170 0.37 PDE4DIP, SEC22B GAIN C3Tag, Myc 
1 145406799 145431022 0.52 HFE2 GAIN C3Tag 
1 145431022 145464501 0.53 TXNIP GAIN C3Tag 
1 145464501 145737051 0.54 ANKRD34A, LIX1L, RBM8A, GNRHR2, PEX11B, PIAS3, NUDT17, POLR3C, RNF115, CD160 GAIN C3Tag, Myc 
1 146101240 148205520 0.57 PRKAB2, FMO5, CHD1L, BCL9, ACP6 GAIN C3Tag, Myc 
1 149850351 149935164 0.59 HIST2H2BE, HIST2H2AC, HIST2H2AB, BOLA1, SV2A, SF3B4, MTMR11 GAIN C3Tag 
1 150102064 150184759 0.61 PLEKHO1 GAIN C3Tag 
1 150184759 150372866 0.62 ANP32E, MRPS21, PRPF3 GAIN C3Tag 
1 150372866 150673482 0.62 TARS2, ECM1, ADAMTSL4, ENSA, GOLPH3L GAIN C3Tag 
1 150673606 150763841 0.62 CTSS GAIN C3Tag 
1 150763841 150908906 0.62 CTSK, ARNT GAIN C3Tag 
1 150929687 151773763 0.62 
LASS2, ANXA9, FAM63A, PRUNE, BNIPL, 
CDC42SE1, MLLT11, GABPB2, SEMA6C, TNFAIP8L2, 
LYSMD1, SCNM1, TMOD4, VPS72, PIP5K1A, PI4KB, 
RFX5, PSMB4, POGZ, CGN, TUFT1, MIR554, SNX27, 
CELF3, MRPL9, TDRKH 
GAIN C3Tag 
1 151773763 151814405 0.61 C2CD4D, LOC100132111 GAIN ClaudinLow, C3Tag 
1 151880387 152067728 0.62 S100A10, S100A11 GAIN ClaudinLow, C3Tag 
1 152067728 152208144 0.62 TCHH, RPTN, HRNR GAIN ClaudinLow, C3Tag 
1 152233280 152643406 0.64 FLG2, CRNN, CRCT1, LCE3C, LCE3B, LCE3A GAIN C3Tag 
1 152661380 153346263 0.64 
KPRP, LCE1F, LCE1E, LCE1C, LCE1B, LCE6A, SMCP, 
IVL, SPRR4, SPRR1A, SPRR3, SPRR1B, SPRR2D, 
SPRR2B, SPRR2E, SPRR2F, SPRR2G, LELP1, LOR, 
PGLYRP3, PGLYRP4 
GAIN C3Tag 
1 153354347 153576396 0.64 S100A8, S100A7A, S100A6, S100A5, S100A4, S100A3 GAIN C3Tag 
1 153576396 154012535 0.63 
S100A16, S100A14, S100A13, C1orf77, SNAPIN, ILF2, 
NPR1, INTS3, SLC27A3, GATAD2B, DENND4B, 
SLC39A1, CREB3L4, JTB, JTB, RPS27 
GAIN C3Tag 
1 154105694 154234864 0.63 TPM3, MIR190B GAIN C3Tag 
1 154270185 154318564 0.62 ATP8B2 GAIN C3Tag 
1 154318564 154670097 0.63 UBE2Q1, ADAR GAIN C3Tag 
1 154807935 155175657 0.62 
PMVK, PYGO2, SHC1, CKS1B, FLAD1, LENEP, 
ZBTB7B, DCST2, DCST1, DPM3, KRTCAP2, TRIM46, 
MUC1, MIR92B 
GAIN C3Tag 
1 155175657 155269798 0.63 GBA, FAM189B, SCAMP3 GAIN C3Tag 
1 155269798 155551091 0.62 FDPS, C1orf104, RUSC1, ASH1L, MIR555, LOC645676 GAIN C3Tag 
1 155556216 155699118 0.62 MSTO1 GAIN C3Tag 
1 155808785 155922229 0.60 SYT11, RIT1, RXFP4 GAIN C3Tag 
1 155936658 156321154 0.60 
SSR2, UBQLN4, RAB25, MEX3A, LMNA, SEMA4A, 
SLC25A44, PMF1, BGLAP, PAQR6, SMG5, TMEM79, 
CCT3, C1orf182 
GAIN C3Tag 
1 156321154 156545720 0.59 RHBG, MEF2D, IQGAP3 GAIN C3Tag 
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1 156545720 156587032 0.60 TTC24, APOA1BP, GPATCH4 GAIN C3Tag 
1 156587032 157009095 0.59 
HAPLN2, BCAN, NES, CRABP2, ISG20L2, MRPL24, 
HDGF, PRCC, SH2D2A, NTRK1, NTRK1, INSRR, 
PEAR1 
GAIN C3Tag 
1 157009095 157324089 0.59 ETV3L, ETV3, CYCSP52 GAIN C3Tag 
1 157324089 157657927 0.58 FCRL5 GAIN C3Tag 
1 157657927 158585877 0.57 FCRL1, CD5L GAIN C3Tag 
1 160043165 160439014 0.57 
KCNJ9, IGSF8, ATP1A2, ATP1A4, CASQ1, DCAF8, 
PEX19, COPA, SUMO1P3, NCSTN, NCSTN, NHLH1, 
VANGL2 
GAIN C3Tag, p53null_Basal 
1 160439014 160626897 0.58 SLAMF6, SLAMF1 GAIN p53null_Luminal 
1 160630352 160735536 0.59 CD48, SLAMF7 GAIN p53null_Luminal 
1 162023809 162694593 0.61 NOS1AP, MIR556, UHMK1, UAP1 GAIN p53null_Basal, p53null_Luminal 
1 162695676 162802177 0.61 HSD17B7 GAIN p53null_Basal, p53null_Luminal 
1 162926083 163194263 0.59 RGS4, RGS5 GAIN p53null_Basal, p53null_Luminal 
1 202542202 202901068 0.45 KDM5B GAIN p53null_Luminal 
1 202992792 203977548 0.45 FMOD GAIN ClaudinLow 
1 204164507 204187207 0.45 GOLT1A GAIN ClaudinLow, p53null_Luminal 
1 204674026 205386068 0.45 NFASC GAIN ClaudinLow, p53null_Luminal 
1 207257303 207792896 0.43 CD55 GAIN ClaudinLow 
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APPENDIX 2 
Chromosome 1 subtype-specific conserved CNAs with frequency >= 15% and concordant with 
gene expression in Humans 
 
Chr 
Start Stop % 
CNA 
Mouse Group 
Concordant DNA/RNA Gene Subtype 
1 76174149 77155253 0.17 GAIN MixedRb_C3Tag , ST6GALNAC3 Basal 
1 78405135 78535584 0.20 GAIN MixedRb_C3Tag , FUBP1 Basal 
1 84505777 84732529 0.21 GAIN MixedRb_C3Tag , PRKACB Basal 
1 84915300 85310085 0.21 GAIN MixedRb_C3Tag , GNG5, GNG5, CTBS, SSX2IP Basal 
1 85311192 85537890 0.21 GAIN MixedRb_C3Tag , MCOLN2 Basal 
1 86037551 86753596 0.22 GAIN MixedRb_C3Tag , CYR61 Basal 
1 86753596 87297758 0.23 GAIN MixedRb_C3Tag , ODF2L, SH3GLB1 Basal 
1 87436385 89979180 0.23 GAIN MixedRb_C3Tag , LMO4, GTF2B, GBP2, GBP6 Basal 
1 91482031 92144933 0.22 GAIN MixedRb_C3Tag , CDC7 Basal 
1 92332865 92754726 0.21 GAIN MixedRb_C3Tag , EPHX4, BTBD8 Basal 
1 94323020 94402263 0.23 GAIN MixedRb_C3Tag , DNTTIP2, GCLM Basal 
1 94402263 94847424 0.22 GAIN MixedRb_C3Tag , ABCA4 Basal 
1 94847424 95095305 0.22 GAIN MixedRb_C3Tag , ABCD3, F3 Basal 
1 95095305 95481339 0.21 GAIN MixedRb_C3Tag , SLC44A3, CNN3 Basal 
1 113655140 116683656 0.22 GAIN MixedRb_C3Tag 
, RSBN1, BCL2L15, AP4B1, DCLRE1B, 
HIPK1, TSPAN2, CASQ2, SLC22A15 Basal 
1 116947174 117783083 0.24 GAIN 
MixedRb_C3Tag, 
p53null2, Wap_Myc , IGSF3, CD101, TRIM45, VTCN1 Basal 
1 118147744 118546081 0.25 GAIN 
MixedRb_C3Tag, 
p53null2 , FAM46C, GDAP2 Basal 
1 119419556 119735326 0.29 GAIN 
MixedRb_C3Tag, 
p53null2 , WARS2 Basal 
1 120315523 144109392 0.35 GAIN 
MixedRb_C3Tag, 
Wap_Myc , NOTCH2 Basal 
1 144369072 145390170 0.37 GAIN 
MixedRb_C3Tag, 
Wap_Myc , PDE4DIP, SEC22B Basal 
1 145464501 145737051 0.54 GAIN 
MixedRb_C3Tag, 
Wap_Myc 
, ANKRD34A, GNRHR2, PEX11B, PIAS3, 
NUDT17, POLR3C, RNF115, CD160 Basal 
1 145792064 150025833 0.50 GAIN MixedRb_C3Tag , BOLA1, SF3B4, MTMR11, OTUD7B LumA 
1 146101240 148205520 0.57 GAIN 
MixedRb_C3Tag, 
Wap_Myc , PRKAB2, FMO5, CHD1L, BCL9, ACP6 Basal 
1 149850351 149935164 0.59 GAIN MixedRb_C3Tag , HIST2H2AC, BOLA1, SF3B4, MTMR11 Basal 
1 150184759 150372866 0.62 GAIN MixedRb_C3Tag , ANP32E, MRPS21, PRPF3 Basal 
1 150189284 150401522 0.50 GAIN MixedRb_C3Tag , ANP32E, MRPS21, PRPF3 LumA 
1 150372866 150673482 0.62 GAIN MixedRb_C3Tag , TARS2, ECM1, ENSA, GOLPH3L Basal 
1 150402288 150677017 0.50 GAIN MixedRb_C3Tag , TARS2, ECM1, ENSA, GOLPH3L LumA 
1 150677017 151008852 0.50 GAIN MixedRb_C3Tag 
, ARNT, SETDB1, LASS2, FAM63A, 
PRUNE LumA 
1 150763841 150908906 0.62 GAIN MixedRb_C3Tag , ARNT Basal 
1 150929687 151773763 0.62 GAIN MixedRb_C3Tag 
, LASS2, FAM63A, PRUNE, BNIPL, 
CDC42SE1, GABPB2, SEMA6C, LYSMD1, 
SCNM1, TMOD4, VPS72, PIP5K1A, 
PI4KB, RFX5, PSMB4, POGZ, CGN, 
SNX27, MRPL9, TDRKH Basal 
1 151062957 151321770 0.50 GAIN MixedRb_C3Tag 
, SEMA6C, LYSMD1, SCNM1, TMOD4, 
VPS72, PIP5K1A, PI4KB, RFX5 LumA 
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1 151321770 151409843 0.50 GAIN MixedRb_C3Tag , PSMB4 LumA 
1 151409843 151575155 0.50 GAIN MixedRb_C3Tag , CGN LumA 
1 151659023 151789548 0.50 GAIN 
MixedGroup, 
MixedRb_C3Tag , MRPL9, TDRKH, LINGO4 LumA 
1 151773763 151814405 0.61 GAIN 
MixedGroup, 
MixedRb_C3Tag , LOC100132111 Basal 
1 151789548 151880754 0.50 GAIN 
MixedGroup, 
MixedRb_C3Tag , LOC100132111 LumA 
1 151880387 152067728 0.62 GAIN 
MixedGroup, 
MixedRb_C3Tag , S100A10, S100A11 Basal 
1 151880754 152292453 0.50 GAIN 
MixedGroup, 
MixedRb_C3Tag , S100A10, S100A11 LumA 
1 153354347 153576396 0.64 GAIN MixedRb_C3Tag , S100A8, S100A6 Basal 
1 153576396 154012535 0.63 GAIN MixedRb_C3Tag 
, S100A16, S100A14, C1ORF77, SNAPIN, 
ILF2, INTS3, GATAD2B, DENND4B, 
SLC39A1, JTB, JTB, RPS27 Basal 
1 154105694 154234864 0.63 GAIN MixedRb_C3Tag , TPM3 Basal 
1 154318564 154670097 0.63 GAIN MixedRb_C3Tag , UBE2Q1, ADAR Basal 
1 154807935 155175657 0.62 GAIN MixedRb_C3Tag 
, PMVK, PYGO2, SHC1, CKS1B, FLAD1, 
ZBTB7B, DCST2, DPM3, KRTCAP2, 
TRIM46, MUC1 Basal 
1 155175657 155269798 0.63 GAIN MixedRb_C3Tag , GBA, FAM189B, SCAMP3 Basal 
1 155269798 155551091 0.62 GAIN MixedRb_C3Tag , RUSC1, LOC645676 Basal 
1 155556216 155699118 0.62 GAIN MixedRb_C3Tag , MSTO1 Basal 
1 155808785 155922229 0.60 GAIN MixedRb_C3Tag , RIT1 Basal 
1 155936658 156321154 0.60 GAIN MixedRb_C3Tag 
, SSR2, UBQLN4, RAB25, MEX3A, 
LMNA, SEMA4A, SLC25A44, PMF1, 
BGLAP, PAQR6, SMG5, TMEM79, 
C1ORF182 Basal 
1 156321154 156545720 0.59 GAIN MixedRb_C3Tag , MEF2D, IQGAP3 Basal 
1 156545720 156587032 0.60 GAIN MixedRb_C3Tag , APOA1BP, GPATCH4 Basal 
1 156587032 157009095 0.59 GAIN MixedRb_C3Tag 
, CRABP2, ISG20L2, MRPL24, HDGF, 
PRCC Basal 
1 157009095 157324089 0.59 GAIN MixedRb_C3Tag , ETV3L Basal 
1 160043165 160439014 0.57 GAIN 
MixedRb_C3Tag, 
p53null1 
, IGSF8, DCAF8, PEX19, NCSTN, NCSTN, 
VANGL2 Basal 
1 160197660 160372346 0.51 GAIN 
MixedRb_C3Tag, 
p53null1, p53null2 , PEX19, NCSTN, NCSTN LumA 
1 160906176 163790065 0.18 GAIN p53null2 
, F11R, USF1, PVRL4, KLHDC9, DEDD, 
DEDD, UFC1, PPOX, B4GALT3, 
ADAMTS4, NDUFS2, NR1I3, NR1I3, 
PCP4L1, C1ORF192, DUSP12, ATF6, 
UHMK1, UAP1, HSD17B7, NUF2 
Claudin-
Low 
1 162023809 162694593 0.61 GAIN p53null1, p53null2 , UHMK1, UAP1 Basal 
1 162695676 162802177 0.61 GAIN p53null1, p53null2 , HSD17B7 Basal 
1 167718720 170486625 0.18 GAIN p53null2 
, ADCY10, DCAF6, DCAF6, GPR161, 
TIPRL, TBX19, NME7, NME7, SLC19A2, 
SCYL3, KIFAP3 
Claudin-
Low 
1 168137580 168255773 0.67 GAIN p53null1, p53null2 , TIPRL LumB 
1 169049881 169622927 0.37 GAIN p53null1, p53null2 , NME7 Her2 
1 169622927 169957961 0.38 GAIN p53null1, p53null2 , SCYL3 Her2 
1 169728459 170031491 0.68 GAIN p53null1, p53null2 , SCYL3 LumB 
1 170453516 170634305 0.68 GAIN p53null2 , GORAB LumB 
1 182988016 184909056 0.18 GAIN p53null2 , SMG7, ARPC5, TSEN15, EDEM3 
Claudin-
Low 
1 202542202 202845388 0.73 GAIN p53null2 , SYT2, KDM5B LumB 
! %,-!
1 202542202 202901068 0.45 GAIN p53null2 , KDM5B Basal 
1 202845388 203372186 0.73 GAIN MixedGroup 
, RABIF, KLHL12, ADIPOR1, CYB5R1, 
PPFIA4, ADORA1, MYBPH, BTG2 LumB 
1 203372186 204393038 0.73 GAIN 
MixedGroup, 
p53null2 
, SOX13, KISS1, GOLT1A, PLEKHA6, 
PPP1R15B LumB 
1 204164507 204187207 0.45 GAIN 
MixedGroup, 
p53null2 , GOLT1A Basal 
1 204393582 204863970 0.73 GAIN 
MixedGroup, 
p53null2 , MDM4, LRRN2 LumB 
1 205035520 205333969 0.73 GAIN MixedGroup , TMEM81, RBBP5, DSTYK, NUAK2 LumB 
1 205333969 206253777 0.73 GAIN MixedGroup 
, CDK18, MFSD4, ELK4, SLC45A3, 
NUCKS1, RAB7L1, SLC41A1, FAM72A LumB 
1 206617766 206976274 0.72 GAIN MixedGroup , IKBKE, DYRK3, MAPKAPK2 LumB 
1 206976766 207086194 0.72 GAIN MixedGroup , IL20 LumB 
1 207086194 207153759 0.71 GAIN MixedGroup , PIGR LumB 
1 207205030 207256205 0.72 GAIN MixedGroup , YOD1, PFKFB2 LumB 
1 207257303 207792896 0.43 GAIN MixedGroup , CD55 Basal 
1 207260606 207864198 0.72 GAIN MixedGroup , CD55 LumB 
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APPENDIX 3 
Top 5% DawnRank Scores 
 
Gene DawnRankPvalue DawnRankRawScore 
PRCC 0.0956 0.8326 
STX6 0.0954 0.8328 
UBE2Q1 0.0944 0.8341 
SNAPIN 0.0942 0.8343 
KLHL12 0.0914 0.8379 
RAP1A 0.0893 0.8407 
CASP9 0.0882 0.8421 
PI4KB 0.0877 0.8428 
GATAD2B 0.0870 0.8437 
GTF2B 0.0867 0.8441 
BPNT1 0.0861 0.8449 
MAPKAPK2 0.0850 0.8464 
SMG5 0.0842 0.8475 
RAB4A 0.0800 0.8533 
DEDD 0.0800 0.8534 
VPS45 0.0776 0.8569 
PSEN2 0.0743 0.8617 
ZBTB17 0.0740 0.8621 
ACTN2 0.0725 0.8643 
NGF 0.0703 0.8677 
LCK 0.0671 0.8727 
JAK1 0.0664 0.8739 
HNRNPU 0.0648 0.8765 
HDAC1 0.0614 0.8822 
GNAI3 0.0596 0.8853 
F11R 0.0577 0.8886 
FCER1A 0.0572 0.8895 
JUN 0.0557 0.8924 
SETDB1 0.0523 0.8987 
CDC42 0.0506 0.9020 
FCGR2B 0.0476 0.9082 
DHX9 0.0465 0.9105 
IKBKE 0.0399 0.9251 
NCSTN 0.0394 0.9264 
FCER1G 0.0390 0.9273 
PTPRC 0.0383 0.9290 
FASLG 0.0377 0.9306 
AKT3 0.0336 0.9411 
ACTA1 0.0315 0.9469 
SHC1 0.0286 0.9558 
CD247 0.0274 0.9593 
! %,&!
POU2F1 0.0265 0.9624 
ARNT 0.0246 0.9688 
ARF1 0.0238 0.9715 
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APPENDIX 4 
Multivariate survival analaysis of prognostic markers 
   
TCGA Variable Univariate P-value 
Hazard 
Ratio 
Multivariate 
FGD5 
Hazard 
Ratio 
Multivariate 
METLL6 
Hazard 
Ratio 
Multivariate 
CPT1A 
Hazard 
Ratio 
FGD5 8.91E-05 3.6120 0.0175 2.6298       
METTL6 0.0006 3.1500     0.0256 2.4917     
CPT1A 0.3720 1.3340       0.4430 1.3574 
DTX3 0.0435 2.0720           
MRPS23 0.0097 2.4250           
EIF2S2 0.7690 1.0990           
EIF6 0.6250 1.1630           
SLC2A10 0.9440 1.0220           
Age 0.0205 1.0280 0.0006 1.0524 0.0006 1.0519 0.0005 1.0537 
Stage 0.5780 1.1040 0.6387 1.0524 0.6645 0.8970 0.6998 0.9104 
ER.Statuspos 0.3850 0.6612 0.1195 0.3805 0.1352 0.3944 0.1728 0.4163 
HER2.Statuspos 0.8210 0.8972 0.0241 0.2007 0.0219 0.1913 0.0305 0.1957 
Node.Status 0.0542 1.3830 0.1907 1.2983 0.2152 1.2787 0.2069 1.2799 
PAM50LumB 0.0078 2.4860 0.7205 1.2335 0.7297 1.2234 0.7911 0.8527 
PAM50Her2 0.0098 2.8210 0.1174 3.3879 0.1210 3.3601 0.2495 2.4861 
Proliferation.Score 0.0006 3.5540 0.1105 2.9367 0.1025 3.0054 0.0182 4.8883 
         
         
TCGA Variable 
(Proliferation 
Excluded) 
Univariate 
P-value 
Hazard 
Ratio 
Multivariate 
FGD5 
Hazard 
Ratio 
Multivariate 
METLL6 
Hazard 
Ratio 
Multivariate 
CPT1A 
Hazard 
Ratio 
FGD5 8.91E-05 3.6120 0.0023 3.2201       
METTL6 0.0006 3.1500     0.0038 3.0597     
CPT1A 0.3720 1.3340       0.4840 1.3285 
DTX3 0.0435 2.0720           
MRPS23 0.0097 2.4250           
EIF2S2 0.7690 1.0990           
EIF6 0.6250 1.1630           
SLC2A10 0.9440 1.0220           
Age 0.0205 1.0280 0.0019 1.0466 0.0018 1.0462 0.0029 1.0466 
Stage 0.5780 1.1040 0.5047 0.8443 0.5305 0.8535 0.5893 0.8765 
ER.Statuspos 0.3850 0.6612 0.1580 0.4361 0.1760 0.4505 0.1969 0.4592 
HER2.Statuspos 0.8210 0.8972 0.0242 0.2016 0.0223 0.1934 0.0351 0.2101 
Node.Status 0.0542 1.3830 0.1318 1.3517 0.1512 1.3303 0.1380 1.3424 
PAM50LumB 0.0078 2.4860 0.0252 2.4405 0.0248 2.4433 0.0451 2.3183 
PAM50Her2 0.0098 2.8210 0.0053 6.4303 0.0055 6.4608 0.0088 6.1336 
         
         
METABRIC 
Variable 
Univariate 
P-value 
Hazard 
Ratio 
Multivariate 
FGD5 
Hazard 
Ratio 
Multivariate 
METLL6 
Hazard 
Ratio 
Multivariate 
CPT1A 
Hazard 
Ratio 
FGD5 1.84E-02 1.719 0.64934 1.2143       
METTL6 0.0090 1.7730     0.5551 1.2620     
CPT1A 0.0996 1.2220       0.3278 1.2281 
DTX3 0.0105 1.6250           
MRPS23 0.0021 1.4080           
EIF2S2 0.0056 1.4530           
EIF6 0.0002 1.6180           
SLC2A10 0.0106 1.3690           
Age 0.0004 1.0160 0.3437 1.0079 0.2761 1.0088 0.1682 1.0114 
Stage 2.83E-05 1.279 0.83096 0.9786 0.6986 1.0376 0.8082 1.024 
ER.Statuspos 1.15E-07 0.4953 0.42202 0.777 0.3262 0.7409 0.2005 0.6674 
! %-)!
HER2.Statuspos 0.0004 1.4010 0.2750 1.1612 0.2034 1.1799 0.2999 1.1503 
Node.Status <2e-16 1.0720 2.37E-07 1.1188 1.83E-07 1.1138 3.31E-08 1.1238 
PAM50LumB 3.24E-08 1.9570 0.6493 1.1546 0.3329 1.3418 0.5780 1.1914 
PAM50Her2 4.00E-15 2.7760 0.7051 1.1592 0.5954 1.2251 0.8446 1.0801 
Proliferation.Score 1.55E-15 2.4800 0.0056 2.3635 0.0164 2.0314 0.0111 2.1539 
         
         
METABRIC 
Variable 
(Proliferation 
Excluded) 
Univariate 
P-value 
Hazard 
Ratio 
Multivariate 
FGD5 
Hazard 
Ratio 
Multivariate 
METLL6 
Hazard 
Ratio 
Multivariate 
CPT1A 
Hazard 
Ratio 
FGD5 1.84E-02 1.719 0.449884 1.3768       
METTL6 0.00903 1.773     0.358892 1.4305     
CPT1A 0.0996 1.222       0.28784 1.2496 
DTX3 0.0105 1.625           
MRPS23 0.00212 1.408           
EIF2S2 0.00557 1.453           
EIF6 0.000158 1.618           
SLC2A10 0.0106 1.369           
Age 0.000415 1.016 0.430909 1.0066 0.378172 1.0071 0.23022 1.0099 
Stage 2.83E-05 1.279 0.902639 0.9877 0.627168 1.0474 0.73455 1.0336 
ER.Statuspos 1.15E-07 0.4953 0.35883 0.7486 0.307927 0.7314 0.17769 0.6521 
HER2.Statuspos 0.000352 1.401 0.261251 1.1657 0.196853 1.1825 0.2907 1.1529 
Node.Status <2e-16 1.072 1.15E-07 1.1231 1.25E-07 1.1164 3.56E-08 1.125 
PAM50LumB 3.24E-08 1.957 0.000957 2.1096 0.000282 2.2106 0.00173 2.045 
PAM50Her2 4.00E-15 2.776 0.017171 2.141 0.019139 2.0753 0.04356 1.9082 
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Multivariate survival analaysis of prognostic markers  (Continued) 
 
TCGA 
Variable 
Multivari
ate 
DTX3 
Hazard 
Ratio 
Multivar
iate 
MRPS23 
Hazard 
Ratio 
Multivar
iate 
EIF2S2 
Hazard 
Ratio 
Multivar
iate 
EIF6 
Hazard 
Ratio 
Multiva
riate 
SCL2A
10 
Hazard 
Ratio 
FGD5               
METTL6               
CPT1A               
DTX3 0.3516 1.4869             
MRPS23   0.2727 1.5937         
EIF2S2       0.5275 0.7736       
EIF6         0.6294 0.8239   
SLC2A10             0.4468 0.7336 
Age 0.0011 1.0519 0.0006 1.0521 0.0003 1.0552 0.0004 1.0546 0.0004 1.0547 
Stage 0.6113 0.8864 0.6346 0.8907 0.6168 0.8875 0.6205 0.8886 0.6091 0.8857 
ER.Statuspo
s 0.1493 0.4052 0.1515 0.4053 0.1965 0.4401 0.2014 0.4422 0.2133 0.4521 
HER2.Status
pos 0.0461 0.2345 0.0272 0.1952 0.0388 0.2184 0.0367 0.2155 0.0404 0.2218 
Node.Status 0.1668 1.3057 0.1278 1.3422 0.1074 1.3849 0.1186 1.3706 0.0982 1.3993 
PAM50Lum
B 0.9972 1.0021 0.8679 0.9091 0.9298 1.0531 0.9568 1.0324 0.8814 1.0926 
PAM50Her2 0.2355 2.4946 0.2503 2.4449 0.2016 2.7165 0.2005 2.7363 0.1916 2.7956 
Proliferation
.Score 0.0355 4.1506 0.0219 4.5151 0.0218 4.6018 0.0217 4.6041 0.0237 4.5122 
           
           
TCGA 
Variable 
(Proliferatio
n Excluded) 
Multivari
ate 
DTX3 
Hazard 
Ratio 
Multivar
iate 
MRPS23 
Hazard 
Ratio 
Multivar
iate 
EIF2S2 
Hazard 
Ratio 
Multivar
iate 
EIF6 
Hazard 
Ratio 
Multiva
riate 
SCL2A
10 
Hazard 
Ratio 
FGD5               
METTL6               
CPT1A               
DTX3 0.1572 1.8168             
MRPS23   0.2256 1.6704         
EIF2S2       0.4275 0.7213       
EIF6         0.5018 0.7613   
SLC2A10             0.3306 0.6733 
Age 0.0063 1.0432 0.0023 1.0459 0.0017 1.0490 0.0021 1.0480 0.0021 1.0480 
Stage 0.4412 0.8331 0.5365 0.8599 0.5627 0.8702 0.5663 0.8710 0.5632 0.8711 
ER.Statuspo
s 0.1583 0.4316 0.1772 0.4500 0.2261 0.4835 0.2384 0.4910 0.2513 0.5002 
HER2.Status
pos 0.0550 0.2518 0.0326 0.2105 0.0424 0.2246 0.0396 0.2203 0.0421 0.2242 
Node.Status 0.0909 1.3824 0.0715 1.4170 0.0532 1.4760 0.0585 1.4625 0.0464 1.4921 
PAM50Lum
B 0.0195 2.4954 0.0441 2.2690 0.0109 2.7622 0.0120 2.7181 0.0095 2.8503 
! %-(!
PAM50Her2 0.0150 5.2160 0.0100 5.7788 0.0066 6.4947 0.0063 6.5935 0.0061 6.6658 
           
           
METABRIC 
Variable 
Multivari
ate 
DTX3 
Hazard 
Ratio 
Multivar
iate 
MRPS23 
Hazard 
Ratio 
Multivar
iate 
EIF2S2 
Hazard 
Ratio 
Multivar
iate 
EIF6 
Hazard 
Ratio 
Multiva
riate 
SCL2A
10 
Hazard 
Ratio 
FGD5               
METTL6               
CPT1A               
DTX3 0.4702 1.2737             
MRPS23   0.3804 0.8397         
EIF2S2       0.2185 1.3234       
EIF6         0.0431 1.5433   
SLC2A10             0.9790 1.0059 
Age 0.2733 1.0088 0.2061 1.0102 0.2951 1.0084 0.3199 1.0080 0.2432 1.0094 
Stage 0.7224 1.0346 0.64839 1.0447 0.7164 1.0351 0.7323 1.033 0.7164 1.0354 
ER.Statuspo
s 0.267 0.7149 0.33076 0.7419 0.2628 0.7126 0.2549 0.7093 0.2765 0.7175 
HER2.Status
pos 0.2412 1.1642 0.2044 1.1789 0.2529 1.1602 0.2635 1.1565 0.2356 1.1667 
Node.Status 1.13E-07 1.1159 2.14E-07 1.1129 1.13E-07 1.114 9.30E-08 1.1142 1.41E-07 1.1142 
PAM50Lum
B 0.3754 1.3103 0.4105 1.2833 0.3482 1.3308 0.3580 1.3241 0.3470 1.3305 
PAM50Her2 0.6461 1.1898 0.7015 1.1567 0.5505 1.2547 0.5112 1.2832 0.6319 1.1996 
Proliferation
.Score 0.0146 2.0493 0.0054 2.3158 0.0262 1.9365 0.0315 1.8944 0.0154 2.0549 
           
           
METABRIC 
Variable 
(Proliferatio
n Excluded) 
Multivari
ate 
DTX3 
Hazard 
Ratio 
Multivar
iate 
MRPS23 
Hazard 
Ratio 
Multivar
iate 
EIF2S2 
Hazard 
Ratio 
Multivar
iate 
EIF6 
Hazard 
Ratio 
Multiva
riate 
SCL2A
10 
Hazard 
Ratio 
FGD5               
METTL6               
CPT1A               
DTX3 0.426052 1.3061             
MRPS23   0.745102 0.9385         
EIF2S2       0.097623 1.4482       
EIF6         0.016634 1.6597   
SLC2A10             0.651409 1.1045 
Age 0.375404 1.0071 0.295207 1.0084 
0.38819
7 1.0069 
0.41361
5 1.0065 
0.33211
8 1.0078 
Stage 0.672986 1.0413 0.601474 1.0514 
0.66522
4 1.0419 
0.67730
9 1.0402 
0.65264
6 1.0439 
ER.Statuspo
s 0.246021 0.7036 
0.26283
3 0.7091 
0.23207
2 0.6962 
0.22631
8 0.6938 
0.23634
9 0.6961 
! %-*!
HER2.Status
pos 0.222193 1.171 
0.21274
3 1.1762 
0.24399
4 1.1632 
0.25402
2 1.1597 
0.22338
2 1.1712 
Node.Status 7.71E-08 1.1186 1.21E-07 1.1163 8.63E-08 1.1157 7.36E-08 1.1157 1.04E-07 1.1162 
PAM50Lum
B 0.000377 2.1815 
0.00025
2 2.2549 
0.00069
9 2.1115 
0.00091
7 2.0756 
0.00039
8 2.1875 
PAM50Her2 0.022442 2.0194 0.02065 2.0738 0.020796 2.0406 
0.01939
1 2.0548 
0.02305
3 2.0247 
 
 !
